CCMD SLIDES: CREATED BY CCMD
|
|
|
Atherosclerotic Progression/Regression
|
|
Atherosclerotic Progression/ Regression
|
|
|
|
|
|
Lp(a): Vascular Events by Sex and Quintile at Baseline (Cardiovascular Health Study)
|
|
CHARISMA: Clopidogrel + Aspirin vs Aspirin Alone in High-Risk CVD Patients
|
|
ASAP: Study Design
|
|
ASAP: Cholesterol-Lowering Results
|
|
ASAP: Primary Parameter Change in Overall Carotid IMT
|
|
EPAT: Baseline Characteristics of Evaluable Patients
|
|
EPAT: Progression of Carotid Artery Intima-Media Thickness (IMT)
|
|
DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes
|
|
ASTEROID: High-Dose Statin Therapy–Effects on Atherosclerosis
|
|
ASTEROID: High-Dose Statin Therapy—Effects on LDL-C and HDL-C
|
|
ASTEROID: High-Dose Statin Therapy—Effects on Discrete Coronary Stenoses
|
|
METEOR: Effects of Statin Therapy on Low-Risk Patients—Primary Endpoint
|
|
METEOR: Effects of Statin Therapy on Low-Risk Patients—Secondary Endpoints
|
|
ENHANCE: Combination Therapy—Primary Outcome
|
|
ENHANCE: Combination Therapy—Effects on Lipoproteins
|
|
SANDS: Study Design
|
|
SANDS: Change in CIMT with Aggressive vs Standard Therapy
|
|
PERISCOPE: Study Design
|
|
PERISCOPE: Change in PAV
|
|
LCAS: Effect on Lipids between Baseline and End of Trial
|
|
LCAS: Primary End Point
|
|
LCAS: Effect of Treatment on Patients Experiencing Progression or Regression
|
|
LCAS: Conclusions
|
|
L-CAD: Comparison of End Points, Change in Lumen Diameters
|
|
HATS: Lipid Levels Before and During Treatment
|
|
HATS: Percent Change in Stenosis
|
|
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale
|
|
IBIS-2: Effects of Lp-PLA2 Inhibitor Darapladib on Coronary Atherosclerotic Plaque
|
|
IBIS-2: Decreases in Progression of Necrotic Core
|
|
PDAY: Percentage of Right Coronary Artery Intimal Surface Affected With Early Atherosclerosis
|
|
PDAY: Prevalence of lesions in LAD
|
|
Post-CABG: Impact of Aggressive vs Moderate Lowering of LDL-C on Atherosclerosis
|
|
Post-CABG Study: Aggressive vs Moderate Treatment
|
|
Post-CABG: End Points, Results, Conclusions
|
|
Post-CABG Angiographic Outcomes
|
|
Post-CABG: Event Rates by Cholesterol Group
|
|
Post-CABG: Aggressive LDL-C Lowering Delays Progression of Atherosclerosis in Women, Elderly, and Patients With Selected CHD Risk Factors
|
|
PROactive: Time to Secondary Endpoint (Death, Nonfatal MI, Stroke)
|
|
REVERSAL: Effect of Moderate vs Intensive Statin Therapy
|
|
Post-CABG: Effect of Aggressive Lipid Lowering on a Subgroup of Patients With Diabetes
|
|
ORION: Study Design
|
|
Effect of Lifestyle Changes on Angiographic CAD
|
|
Lp(a) in Atherogenesis: Another Culprit?
|
|
Homocysteine: Role of Atherogenesis
|
|
Continuum of Patients at Risk for a CHD Event
|
|
Coronary Artery Calcification (CAC) and CHD Family History
|
|
Ethnic Disparities in CVD Risk Factors in the US Population
|
|
US Death Rates From CVD by Ethnicity and Sex, 1980-2001
|
|
Smoking-Related CV Mortality in Year 2000
|
|
Trends in Total Cholesterol for US Adults, 1960-1962 to 1999-2002
|
|
WISE Study: Review of Ischemic Heart Disease in Women
|
|
Treatment Options for Peripheral Arterial Disease
|
|
Treatment Options for Peripheral Arterial Disease (cont)
|
|
Trans-Fatty Acid Intake and Relative Risk for CHD
|
|
4S: Effect of Cholesterol Lowering on Noncoronary Ischemic Symptoms and Angina
|
|
Lipid Lowering and Plaque Regression: Monotherapy Studies
|
|
Event Reduction in Angiographic Plaque Regression Trials
|
|
Association Between Change in Lumen Size and Coronary Events: Important Factors
|
|
Effects of Lipid-Lowering Therapy on Endothelial Function in CHD Patients
|
|
Effect of Cholesterol Lowering on Myocardial Ischemia
|
|
Atherosclerosis: A Progressive Process
|
|
The Anatomy of Atherosclerotic Plaque
|
|
Angiographically Inapparent Atheroma
|
|
The Matrix Skeleton of Unstable Coronary Artery Plaque
|
|
Histologic Stain of Plaque
|
|
Characteristics of Plaques Prone to Rupture
|
|
Updated Model of Lipoprotein Metabolism and Reverse Cholesterol Transport
|
|
TGs Predict CAD Risk Independently of TC and HDL-C
|
|
Hypertriglyceridemia and CHD Risk: Associated Abnormalities
|
|
Association of Small, Dense LDL With Myocardial Infarction
|
|
Responses to a 75-g Oral Glucose Challenge in Relation to LDL Particle Diameter
|
|
Characteristics of LDL Phenotype B
|
|
Cumulative Distribution of Adjusted Plasma TG Levels: LDL Phenotypes A and B
|
|
Cumulative Distribution of Adjusted HDL-C: LDL Phenotypes A and B
|
|
Interrelation Between Atherosclerosis and Insulin Resistance
|
|
Composite CIMT With Metabolic Syndrome in Young Adults
|
|
Progression to Atherosclerotic Clinical Events in Patients With Diabetes
|
|
Atherosclerosis in Diabetes
|
|
Insulin Resistance and Atherosclerosis: Posited Relationships
|
|
Significance of Small, Dense LDL
|
|
Effects of Atorvastatin on CRP and Endothelial Function in Type 2 Diabetes
|
|
Relation Between Change in CRP Endothelium-Dependent Vasodilation With Atorvastatin in Type 2 Diabetes (6 Months)
|
|
Effects of Lipid Lowering on Endothelial Function: Hypercholesterolemic Patients
|
|
Effects of Lipid-Lowering Therapy on Myocardial Perfusion in CHD Patients
|
|
Lowest Effective Aspirin Dose for MI and Stroke Reduction
|
|
Metabolic Syndrome and 10-Year CVD Risk
|
|
Potential Mechanisms of Atherogenesis in Diabetes
|
|
Impact of Statin-Induced Changes in LDL-C and HDL-C on Atheroma Burden (1 of 2)
|
|
Impact of Statin-Induced Changes in LDL-C and HDL-C on Atheroma Burden (2 of 2)
|
|
Association of Subclinical Atherosclerosis Outcomes With 10-Year FRS
|
|
CAC Cutoffs by 10-Year CHD Event Risk Among CVD-Free Subjectsa
|
|
CVD Event Prediction Among Subjects With Subclinical Atherosclerosis and Low HDL-C
|
|
CVD Event Prediction Among Subjects With Subclinical Atherosclerosis and Low HDL-C: 5-Year Follow-Up
|
|
Use of CRP to Assess CVD Risk Across Age Groups: Study Design
|
|
Effect of Statins on Atherosclerosis After ACS: Design
|
|
Effect of Statins on Atherosclerosis After ACS: Percent Change in Atheroma Volume
|
|
Intensive Lifestyle Interventions: Effects on Endothelial Function and Inflammatory Markers Design
|
|
Intensive Lifestyle Interventions: Effects on Endothelial Function and Inflammatory Markers Results
|
|
Clinical Guidelines
|
|
ATP III
|
|
|
|
|
SEACOAST: Combination Therapy for Increased Non–HDL-C
Primary Endpoint
|
|
ATP III: Features Shared With ATP II
|
|
ATP III: LDL-C, HDL-C, TC Classification
|
|
ATP III: Major CHD Risk Factors Other Than LDL-C
|
|
ATP III: Additional CHD Risk Factors
|
|
ATP III: Assessment of Risk
|
|
ATP III: Risk Categories, LDL-C Goals
|
|
ATP III: CHD Risk Equivalents
|
|
ATP III: LDL-C Treatment Cutpoints for Therapy
|
|
ATP III: Nutritional Components of the TLC Diet
|
|
ATP III: Additional Dietary Options for LDL-C Lowering
|
|
ATP III: Management of Elevated TG
|
|
ATP III: The Metabolic Syndrome
|
|
ATP III: Management of Diabetic Dyslipidemia
|
|
ATP III: LDL-C Measurements in Patients Hospitalized for Major Coronary Events
|
|
ATP III: Special Populations—Women, Middle-Aged Men
|
|
ATP III: Improving Adherence—Focus on the Patient
|
|
ATP III: Improving Adherence—Focus on the Physician, Delivery System
|
|
ATP III Framingham Risk Scoring–Assessing CHD Risk in Men
|
|
ATP III Framingham Risk Scoring–Assessing CHD Risk in Women
|
|
ATP III Framingham Risk Scoring–Step 1: Age
|
|
ATP III Framingham Risk Scoring–Step 2: Total Cholesterol
|
|
ATP III Framingham Risk Scoring–Step 3: HDL-Cholesterol
|
|
ATP III Framingham Risk Scoring–Step 4: Systolic Blood Pressure
|
|
ATP III Framingham Risk Scoring–Step 5: Smoking Status
|
|
ATP III Framingham Risk Scoring Step 6: Adding Up the Points (Sum From Steps 1–5)
|
|
ATP III Framingham Risk Scoring–Step 7: CHD Risk for Women
|
|
ATP III Framingham Risk Scoring Step 7: CHD Risk for Men
|
|
Update to ATP III Guidelines: Rationale
|
|
Update to ATP III Guidelines: Rationale (cont'd)
|
|
ATP III: Updated LDL-C Goals, Treatment Cutpoints
|
|
ATP III: Updated LDL-C Goals, Treatment Cutpoints (cont'd)
|
|
Eligible Primary-Prevention Patients by Age and Treatment Scenario (ATP III vs ATP II)
|
|
ATP III: Management of Very High LDL-C
|
|
ATP III: Management of Low HDL-C
|
|
ATP III: Special Populations—Older Adults, Younger Adults
|
|
ATP III vs ATP II: Increases in Treatment-Eligible Primary-Prevention Patients
|
|
NHANES Extrapolation: Population Meeting JUPITER Study Eligibility
|
|
Population Estimatesa at ATP III Risk Categories with CRP ≥2 mg/L
|
|
Other
|
|
|
|
|
|
Cost of CHD in the United States
|
|
Cost of CVD and Stroke in the United States
|
|
US Cost of Health Expenditures, Lost Productivity of CVD and Stroke
|
|
JNC 7: Treatment Algorithm for Hypertension
|
|
AHA/CDC Panel: Recommendations for Use of hs-CRP in Clinical Practice
|
|
AHA/CDC Panel: Recommendations for hs-CRP Laboratory Testing
|
|
Prevalence of Class 3 Obesity in the United States: BRFSS 2000
|
|
BMI: Adjusted Odds Ratios for Unstable Coronary Artery Disease
|
|
AHA Get With the Guidelines: Adherence to Treatment Measures
|
|
AHA Evidence-Based Guidelines for CVD Prevention in Women
|
|
CV Mortality Risk With NCEP-MetS vs WHO-MetS
|
|
Updated Criteria for Clinical Diagnosis of Metabolic Syndrome
|
|
Statin Advisory: Definitions of Muscle Toxicity
|
|
Statin Advisory: Monitoring Parameters, Follow-Up Schedule
|
|
Statin Advisory: Clinical Precautions When Prescribing Statin Therapy
|
|
Statin Advisory: Risk Factors for Statin-Associated Myopathy
|
|
Statin Advisory: Conclusions
|
|
ADA: Glycemic Control, BP, and Lipid Targets in Type 2 Diabetes
|
|
ADA: Treatment Decisions by LDL-C Levels in Adults With Type 2 Diabetes
|
|
Overview: Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)
|
|
Consensus Recommendations for Lp-PLA2 Testing
|
|
NHANES Extrapolation: Population Meeting JUPITER Study Eligibility
|
|
Population Estimatesa at ATP III Risk Categories with CRP ≥2 mg/L
|
|
Use of CRP to Assess CVD Risk Across Age Groups: Study Design
|
|
AHA 2010 Heart Disease and Stroke Statistics: Prevalence and Cost
|
|
AHA 2010 Heart Disease and Stroke Statistics: Incidence
|
|
AHA 2010 Heart Disease and Stroke Statistics: Mortality
|
|
AHA Heart Disease and Stroke Statistics: Diabetes Prevalence
|
|
AHA Heart Disease and Stroke Statistics: Diabetes Mortality
|
|
American Diabetes Association
|
|
|
|
|
|
ADA Criteria for the Diagnosis of Diabetes
|
|
ADA Criteria for Testing for Diabetes in Asymptomatic Adults
|
|
ADA Guidelines for Foot Care in Patients With Diabetes
|
|
ADA Guidelines for Foot Care in Patients With Diabetes (cont)
|
|
ADA Guidelines for Retinopathy Management in Diabetes
|
|
ADA Guidelines for Type 2 Diabetes in Children and Adolescents: Screening and Treatment
|
|
ADA Guidelines for Treatment of Older Adults With Diabetes
|
|
ADA Nutrition Strategies for Weight Loss
|
|
ADA Recommendations for Medical Nutrition Therapy
|
|
ADA Recommendations for Primary Prevention of Diabetes With Medical Nutrition Therapy
|
|
ADA Recommendations for Aspirin Therapy in Diabetes
|
|
ADA Recommendations for Diabetes Care in the Hospital
|
|
ADA Recommendations for Diabetes Care in the Hospital (cont)
|
|
ADA Recommendations for Smoking Cessation in Diabetes
|
|
ADA Treatment Recommendations for Nephropathy
|
|
ADA: Goals for Glycemic, Blood Pressure, and Lipid Control
|
|
ADA: Physical Activity/Exercise Recommendations for Patients With Diabetes
|
|
ADA Recommendations on Bariatric Surgery in Patients With Diabetes
|
|
ADA Recommendations for Immunization in Patients With Diabetes
|
|
ADA Guidelines: Correlation of A1C With Average Glucose
|
|
ADA Recommendations for Neuropathy Screening and Treatment
|
|
ADA: Categories of Increased Risk for Diabetes (Prediabetes)
|
|
ADA Recommendations for Detection and Diagnosis of Gestational Diabetes Mellitus
|
|
ADA Guidelines: Common Comorbidities Associated With Diabetes
|
|
ADA Guidelines: A1C Recommendations
|
|
ADA Guidelines: Glycemic Recommendations for Nonpregnant Adults With Diabetes
|
|
ADA Guidelines: Recommendations for Type 2 Diabetes Therapy
|
|
ADA Guidelines: Recommendations for Hypoglycemia
|
|
ADA Guidelines: Recommendations for Prevention/Delay of Type 2 Diabetes
|
|
ADA Guidelines: Recommendations for Diabetes Self-Management Education (DSME)
|
|
ADA Guidelines: Noninsulin Therapies for Hyperglycemia in Type 2 Diabetes (1 of 2)
|
|
ADA Guidelines: Noninsulin Therapies for Hyperglycemia in Type 2 Diabetes (2 of 2)
|
|
ADA/AHA/ACC: Recommendations for Use of Aspirin for Primary Prevention of CV Events in People With Diabetes
|
|
ADA Nutrition Strategies, Interventions for Improved Metabolic Control
|
|
ADA Criteria for Testing for Diabetes in Asymptomatic Adults
|
ADA Guidelines for Foot Care in Patients With Diabetes
|
ADA Guidelines for Foot Care in Patients With Diabetes (cont)
|
ADA Guidelines for Retinopathy Management in Diabetes
|
ADA Guidelines for Type 2 Diabetes in Children and Adolescents: Screening and Treatment
|
ADA Guidelines for Treatment of Older Adults With Diabetes
|
ADA Nutrition Strategies for Weight Loss
|
ADA Recommendations for Medical Nutrition Therapy
|
ADA Recommendations for Primary Prevention of Diabetes With Medical Nutrition Therapy
|
ADA Recommendations for Aspirin Therapy in Diabetes
|
ADA Recommendations for Diabetes Care in the Hospital
|
ADA Recommendations for Diabetes Care in the Hospital (cont)
|
ADA Recommendations for Smoking Cessation in Diabetes
|
ADA Treatment Recommendations for Nephropathy
|
ADA: Goals for Glycemic, Blood Pressure, and Lipid Control
|
ADA: Physical Activity/Exercise Recommendations for Patients With Diabetes
|
ADA Recommendations on Bariatric Surgery in Patients With Diabetes
|
ADA Recommendations for Immunization in Patients With Diabetes
|
ADA Guidelines: Correlation of A1C With Average Glucose
|
ADA Recommendations for Neuropathy Screening and Treatment
|
ADA: Categories of Increased Risk for Diabetes (Prediabetes)
|
ADA Recommendations for Detection and Diagnosis of Gestational Diabetes Mellitus
|
ADA Guidelines: Common Comorbidities Associated With Diabetes
|
ADA Guidelines: A1C Recommendations
|
ADA Guidelines: Glycemic Recommendations for Nonpregnant Adults With Diabetes
|
ADA Guidelines: Recommendations for Type 2 Diabetes Therapy
|
ADA Guidelines: Recommendations for Hypoglycemia
|
ADA Guidelines: Recommendations for Prevention/Delay of Type 2 Diabetes
|
ADA Guidelines: Recommendations for Diabetes Self-Management Education (DSME)
|
ADA Guidelines: Noninsulin Therapies for Hyperglycemia in Type 2 Diabetes (1 of 2)
|
ADA Guidelines: Noninsulin Therapies for Hyperglycemia in Type 2 Diabetes (2 of 2)
|
Clinical Trials
|
|
A-F
|
|
|
|
|
|
Lp(a): An Independent CHD Risk Factor in Men of the Framingham Offspring Cohort
|
|
Lp(a): Vascular Events by Sex and Quintile at Baseline (Cardiovascular Health Study)
|
|
AFCAPS/TexCAPS: RR of Acute Coronary Events—LDL-C and Homocysteine
|
|
AFCAPS/TexCAPS: RR of Acute Coronary Events—TC: HDL-C Ratio and CRP Level
|
|
AFCAPS/TexCAPS: Effects of LDL C Lowering in Patients With Average Cholesterol Levels
|
|
ACCESS: Change in LDL-C, Non–HDL-C in All Patients at 54 Weeks
|
|
4S: Effect of LDL-C Lowering on Coronary Events in Secondary Prevention Trial in Men and Women
|
|
4S: Findings From a Post Hoc Analysis
|
|
4S: Lipid Lowering Reduces CHD Event Rates in >65-Year Old Subjects
|
|
4S: Impact of Drug Therapy on Lipids and Lipoproteins in Older Adults With Hypercholesterolemia
|
|
4S: Reduction in Coronary Events and Revascularizations in Older Adults With Established CHD
|
|
4S: Survival of Major Coronary Events in Older Adults
|
|
4S: Clinical and Economic Benefits of Treatment Over 5-Yr Period
|
|
CARE: Effect of Lipid Lowering on Lipid Values and Coronary Events in CHD Patients With Average Cholesterol
|
|
CARE: Fatal CHD or Nonfatal MI (Primary End Point)
|
|
CARE: Secondary End Points
|
|
CARE: Findings From a Post Hoc Analysis
|
|
CARE: Impact of Drug Therapy on Lipids and Lipoproteins in Older Patients With MI
|
|
CARE: Reduction in Coronary Events, Revascularizations, and Stroke in Older Adults With MI and Average Cholesterol Levels
|
|
CARE: Incidence of Coronary Events in Younger Versus Older Patients
|
|
AFCAPS/TexCAPS: Primary End Point Event Rates Within Demographic and Risk Factor Subgroups
|
|
A to Z Trial: Primary End Point
|
|
A to Z Trial: Secondary End Points and Adverse Events
|
|
CHARISMA: Clopidogrel + Aspirin vs Aspirin Alone in High-Risk CVD Patients
|
|
Impact of TG Levels on Relative Risk of CHD: Framingham Heart Study
|
|
Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes
|
|
Finnish Diabetes Prevention Study: Success in Achieving Treatment Goals at 1 Year
|
|
Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes
|
|
Diabetes Prevention Program: Study Design
|
|
Diabetes Prevention Program
|
|
The CURVES Trial: A Comparison of LDL-C Lowering Among Statins
|
|
The CURVES Trial: Comparative LDL-C Reductions
|
|
ASAP: Study Design
|
|
ASAP: Cholesterol-Lowering Results
|
|
ASAP: Primary Parameter Change in Overall Carotid IMT
|
|
EPAT: Baseline Characteristics of Evaluable Patients
|
|
EPAT: Progression of Carotid Artery Intima-Media Thickness (IMT)
|
|
AVERT: Study Design and Inclusion Criteria
|
|
AVERT: Major Exclusion Criteria
|
|
AVERT: Overview of Study Procedures
|
|
AVERT: Primary Efficacy Assessment
|
|
AVERT: Secondary Efficacy Assessments
|
|
AVERT: Baseline Patient Characteristics
|
|
AVERT: Ischemic Events
|
|
AVERT: Ischemic Events
|
|
AVERT: Time to First Ischemic Event
|
|
AVERT: Summary of Lipid Parameters
|
|
AVERT: Incidence of First Ischemic Event by Time
|
|
AVERT: Safety Evaluation
|
|
AVERT: Conclusions
|
|
ALLHAT-LLT: All-Cause Mortality
|
|
ALLHAT-LLT: Comparison to Other Large, Long-Term Statin Trials
|
|
ASCOT–LLA: Study Design
|
|
ASCOT-LLA: Primary End Point
|
|
ASCOT-LLA: Primary End Point in Subgroups
|
|
ASCOT-LLA: Secondary End Points
|
|
ASCOT-LLA: Effect of Atorvastatin vs Placebo on CV and Coronary End Points
|
|
FIELD: Fenofibrate Effect on Lipids
|
|
DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes
|
|
DAIS: Mean Baseline Lipoprotein Levels
|
|
DAIS: Interim Lipid Results in Patients With Type 2 Diabetes
|
|
DAIS: Final Results in Patients With Types 2 Diabetes
|
|
Framingham Heart Study 30-Year Follow-Up: CVD Events in Patients With Diabetes (Ages 35-64)
|
|
Abnormal Lipid Levels in Men With Type 2 Diabetes
|
|
Abnormal Lipid Levels in Women With Type 2 Diabetes
|
|
Secondary Prevention: CHD Risk Reduction in the 4S Subgroup of Patients WIth Diabetes
|
|
4S: Total Mortality Reduction in a Subgroup of Patients With Diabetes
|
|
4S: Major CHD Event Reduction in a Subgroup of Patients With Diabetes
|
|
4S: Treatment Benefit in Subgroup With Impaired Fasting Glucose (FG 110-125 mg/dL)
|
|
CARE: Reduction of Coronary Events in Patients With Diabetes
|
|
CARE: Major Coronary Events in the Diabetic Subgroup
|
|
ARIC: CHD Events, CVD Mortality With/Without MI or Diabetes
|
|
Collaborative Atorvastatin Diabetes Study (CARDS): Results Summary
|
|
Collaborative Atorvastatin Diabetes Study (CARDS): Major CVD Events
|
|
CARDS: Effect of Treatment on Primary and Secondary End Points
|
|
ASTEROID: High-Dose Statin Therapy–Effects on Atherosclerosis
|
|
CARDS: Effect of Treatment on Primary End Point by Lipid Level
|
|
ASTEROID: High-Dose Statin Therapy—Effects on LDL-C and HDL-C
|
|
ASTEROID: High-Dose Statin Therapy—Effects on Discrete Coronary Stenoses
|
|
ENHANCE: Combination Therapy—Primary Outcome
|
|
ENHANCE: Combination Therapy—Effects on Lipoproteins
|
|
ACCORD: Study Design
|
|
ACCORD: A1c Levels, Hypoglycemia, and Weight Gain
|
|
ACCORD: Death from Any Cause
|
|
ACCORD: Results
|
|
ADVANCE: Study Design
|
|
ADVANCE: A1c Levels, Hypoglycemia, and End-Study Weight
|
|
ADVANCE: Primary Endpoints
|
|
ADVANCE: Death from Any Cause
|
|
DIACOR Substudy: Effects of Simvastatin and/or Fenofibrate on Lipoprotein Subparticles
|
|
DIACOR Substudy: Level of LDL Pattern B at Baseline and Week 12
|
|
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
|
|
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
|
|
ACCORD BP: Effects of Intensive BP_Control on Type 2 Diabetes
|
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Design
|
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Results
|
|
Trends in CHD Risk Among Adults With Diabetes: Design
|
|
Trends in CHD Risk Among Adults With Diabetes: Results
|
|
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye: Substudy of ACCORD
|
|
ACCORD Eye: Progression of Diabetic Retinopathy By Treatment Group at Year 4
|
|
ACCORD Eye: Moderate Vision Loss By Treatment Group at Year 4
|
|
CANOE: Low-Dose Combination Therapy With Rosiglitazone Plus Metformin for Diabetes Prevention
|
|
CANOE: Development of New-Onset Diabetes With Low-Dose Combination Therapy Vs Placebo
|
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Results
|
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Additional Results at Year 1
|
|
Effect of Statins on Atherosclerosis After ACS: Design
|
|
Effect of Statins on Atherosclerosis After ACS: Percent Change in Atheroma Volume
|
|
Omega-3 Acid Ethyl Esters in Addition to Statin Therapy: Effects on Lipoprotein Particle Concentrations
|
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Design
|
|
ARBITER--6 HALTS: Effect of Niacin ER or Ezetimibe on CIMT
|
|
Results from ARBITER 6--HALTS: Effect of Niacin ER or Ezetimibe on CIMT
|
|
Use of CAC Score for CHD Prediction: Results
|
|
ARBITER 6–Halts: Methods and Final Results
|
|
ARBITER 6–HALTS: Final Results
|
|
G-L
|
|
|
|
|
|
Look AHEAD: Design
|
|
Look AHEAD: Interventions
|
|
Look AHEAD: Change in Body Weight Across BMI Groups
|
|
Look AHEAD: Change in Fitness Levels Across BMI Groups
|
|
Look AHEAD: Additional Results
|
|
LRC Follow-up Study: CVD Mortality by Non–HDL-C and LDL-C in Men
|
|
LRC Follow-up Study: CVD Mortality by Non-HDL-C and LDL-C in Women
|
|
L-TAP: Majority of Patients With CHD Do Not Reach NCEP LDL-C Targets
|
|
L-TAP: Majority of High-Risk Patients Without CHD Do Not Reach NCEP LDL-C Targets
|
|
L-TAP: Patient Success in Achieving Target LDL-C Levels
|
|
Lyon Diet Heart Study: Cumulative Survival Without Cardiac Death and Nonfatal MI
|
|
LIPID: Effect of Lipid Lowering on Lipid Values and Coronary Events in CHD Patients With Average Cholesterol
|
|
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Sex
|
|
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Diabetic Status
|
|
LIPID: Reduction in nonfatal MI and CHD Death Risk Stratified by Prerandomization Age
|
|
LIPID Trial Follow-Up: Cardiovascular Events Over 8 Years
|
|
LIPID Trial Follow-Up: Serious Adverse Events Over 8 Years
|
|
LCAS: Effect on Lipids between Baseline and End of Trial
|
|
LCAS: Primary End Point
|
|
LCAS: Effect of Treatment on Patients Experiencing Progression or Regression
|
|
LCAS: Conclusions
|
|
Heart Protection Study (HPS): Elibigility
|
|
HPS: Design and Interventions
|
|
HPS: End Points for Lipid Lowering
|
|
HPS: Effects of Simvastatin on Cause-Specific Mortality
|
|
HPS: Effects of Simvastatin on First major Vascular Event
|
|
HPS: Effects of Simvastatin on Vascular Events by Year
|
|
HPS: Effects of Simvastatin on Vascular Events by LDL-C
|
|
HPS: Absolute Risk Reductions
|
|
Heart Protection Study (HPS): End Points for Antioxidant Vitamin Supplementation
|
|
HPS: Effects of Antioxidant Vitamins on Cause-Specific Mortality
|
|
HPS: Effects of Antioxidant Vitamins on First Major Vascular Event
|
|
HPS: Effects of Antioxidant Vitamins on Vascular Events by Year
|
|
HPS: Effects of Antioxidant Vitamins on Vascular Events by LDL-C
|
|
Fasting TG and Risk for CHD: Helsinki Heart Study
|
|
HIT: Favorable Effects of Fibrate on CVD Events in CHD Patients With Isolated Low HDL-C
|
|
HERS: Combined HRT Does Not Decrease All-Cause Mortality
|
|
HERS: Primary CHD Events
|
|
HERS: HDL-C Distribution in a Cohort With CHD
|
|
HERS, HERS II: Relative Hazard of CHD Events
|
|
L-CAD: Effect of Intensive Therapy Post-ACS on Lipid Values
|
|
L-CAD: Comparison of End Points, Change in Lumen Diameters
|
|
HATS: Lipid Levels Before and During Treatment
|
|
HATS: Percent Change in Stenosis
|
|
IDEAL Study: Secondary End Points
|
|
IDEAL Study: Effect of Treatment on LDL-C
|
|
Primary CHD Prevention in Patients With Type 2 Diabetes: The Helsinki Heart Study
|
|
HPS Substudy: First Major Vascular Event and Patients With Diabetes
|
|
HPS Substudy: First Major Coronary Event and Stroke by Prior to Diabetes Status
|
|
HPS Substudy: First Major Vascular Event by LDL-C and Prior Diabetes Status
|
|
HPS Diabetes Substudy: Absolute Effects on 5-Year Rates of First Major Vascular Event
|
|
HERS: Risk of Cerebrovascular Disease Events
|
|
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Participant Profile
|
|
IBIS-2: Effects of Lp-PLA2 Inhibitor Darapladib on Coronary Atherosclerotic Plaque
|
|
IBIS-2: Decreases in Progression of Necrotic Core
|
|
JELIS: Study Design
|
|
JELIS: Multiple Risk Factorsa and Incidence of Major Coronary Events
|
|
JELIS: Effects of EPA on Major Coronary Events in Subjects With High TG/Low HDL-C
|
|
JPAD: Study Design
|
|
JPAD Results: Primary Endpoint (CVD Composite)
|
|
JPAD Results: Primary Endpoint in Subgroups
|
|
JUPITER: Study Design
|
|
JUPITER: Lipid and Hs-CRP Levels
|
|
JUPITER Results: Primary Endpoint
|
|
JUPITER Results: Components of Primary Endpoint
|
|
JUPITER Results: Summary
|
|
PROactive: Time to Secondary Endpoint (Death, Nonfatal MI, Stroke)
|
|
NHANES Extrapolation: Population Meeting JUPITER Study Eligibility
|
|
Population Estimatesa at ATP III Risk Categories with CRP ≥2 mg/L
|
|
LOADD: Primary Endpoint—Difference in A1C at 6 Months
|
|
JUPITER Statin Use for Primary Prevention of CVD Events in Women
|
|
Meta-Analysis: Statin Use for Primary Prevention of CVD Events in Women
|
|
M-R
|
|
|
|
|
|
METEOR: Effects of Statin Therapy on Low-Risk Patients—Primary Endpoint
|
|
METEOR: Effects of Statin Therapy on Low-Risk Patients—Secondary Endpoints
|
|
NOMAS: Study Design
|
|
NOMAS: Event-Free Curves Based on MetSyn and Endothelial Dysfunction
|
|
PERISCOPE: Study Design
|
|
PERISCOPE: Change in PAV
|
|
MESA: Study Design
|
|
MESA: CVD and CHD Risk by CIMT or CAC Score
|
|
PREMIER: Percentage of All Participants With Hypertension (6 mo)
|
|
PREMIER: Percentage of All Participants With Optimal Blood Pressure (6 mo)
|
|
JNC 7: Classification and Management of Blood Pressure for Adults
|
|
PRINCE: Change in CRP Levels at 24 Weeks
|
|
PDAY: Percentage of Right Coronary Artery Intimal Surface Affected With Early Atherosclerosis
|
|
PDAY: Prevalence of lesions in LAD
|
|
PDAY: Prevalence of Risk Factors
|
|
PDAY: Prevalence of Lesions by Smoking and Non-HDL-C Status
|
|
Age-Adjusted Total Cholesterol Levels in NHANES III vs NHANES 1999-2000
|
|
NHANES I Epidemiologic Follow-up Study: CHD Incidence and Survival in African American Men and Women
|
|
Adult Population Not Reaching LDL-C Targets
|
|
Prevalence of Overweight in US Men: NHANES 1999-2000
|
|
Prevalence of Overweight in US Women: NHANES 1999-2000
|
|
Prevalence of Obesity in US Men: NHANES 1999-2000
|
|
Prevalence of Obesity in US Women: NHANES 1999-2000
|
|
Post-CABG: Impact of Aggressive vs Moderate Lowering of LDL-C on Atherosclerosis
|
|
Post-CABG Study: Aggressive vs Moderate Treatment
|
|
Post-CABG: End Points, Results, Conclusions
|
|
Post-CABG Angiographic Outcomes
|
|
Post-CABG: Event Rates by Cholesterol Group
|
|
Post-CABG: Aggressive LDL-C Lowering Delays Progression of Atherosclerosis in Women, Elderly, and Patients With Selected CHD Risk Factors
|
|
PROSPER: Primary Composite End Point Results CHD Death, Nonfatal MI, Fatal or Nonfatal Stroke
|
|
PROSPER: Secondary End Point Results
|
|
PROSPER: Rate of CHD-Related Death
|
|
Hypertriglyceridemia—An Independent Risk Factor for CHD: PROCAM Study
|
|
Fasting TG and Risk for CHD Death: Paris Prospective Study
|
|
CHD Mortality and Hyperinsulinemia: Paris Prospective Study (N=943)
|
|
Relation Between Baseline Fasting Insulin and Ischemic Heart Disease
|
|
NHANES III: Age-Adjusted Prevalence of Individual Risk Factors for the Metabolic Syndrome
|
|
NHANES III: Age-Adjusted Prevalence of >3 Risk Factors for the Metabolic Syndrome
|
|
NHANES III: Age-Specific Prevalence of the Metabolic Syndrome
|
|
Impact of Estrogen and Progestin on Cholesterol Concentrations
|
|
HRT Effects on C-Reactive Protein Levels: PEPI Trial Subgroup
|
|
MORE: Cardiovascular Events at 4-Year Follow-up
|
|
Prospective Pravastatin Pooling (PPP) Project: 112,000 Patient-Year Experience
|
|
MIRACL: Study Rationale
|
|
MIRACL: Study Design
|
|
MIRACL: Major Exclusion Criteria
|
|
MIRACL: Outcome Measures
|
|
MIRACL: Baseline Patient Characteristics
|
|
MIRACL: Change in Lipid Levels
|
|
MIRACL: Time to First Ischemic Event
|
|
MIRACL: Occurrence of Primary Combined End Point
|
|
MIRACL: Fatal or Nonfatal Stroke
|
|
MIRACL: Conclusions and Implications
|
|
PRISM: Event Rate Curves
|
|
REVERSAL: Effect of Moderate vs Intensive Statin Therapy
|
|
PROVE-IT: Median LDL-C Levels During Study
|
|
PROVE-IT: Primary Composite End Point
|
|
Post-CABG: Effect of Aggressive Lipid Lowering on a Subgroup of Patients With Diabetes
|
|
ORION: Study Design
|
|
ORION: Effects of Rosuvastatin on Change in Carotid Plaque Volume, Composition
|
|
PREDICT: Study Design
|
|
PREDICT: Primary Endpoint Event Rates in Successive Categories of CAC Score
|
|
PROVE-IT Substudy: Major Safety Outcomes
|
|
PROactive 10 Substudy: Time to First Event from MACE Endpointa
|
|
PROactive 10 Substudy: Time to CV Death, Nonfatal MIa, Nonfatal Stroke
|
|
PROactive 10 Substudy: Time to All-Cause Mortality, Nonfatal MIa, Nonfatal Stroke, or ACS
|
|
PROSPER: Association of Leptin With Diabetes
|
|
PROSPER: Association of Leptin With CVD
|
|
PROSPER: Association of Leptin With CVD
|
|
PROSPER: Association of Leptin With Diabetes
|
|
RECORD: Study Design
|
|
RECORD: CV Death and Hospitalization
|
|
RECORD: Time to Primary Endpoint
|
|
RECORD: Bone Fracture Rates in Upper and Distal Lower Limbs
|
|
RECORD: Conclusion
|
|
NHANES: Gender Differences in Prevalence of Myocardial Infarction
|
|
NHANES: Gender Differences in Coronary Risk
|
|
Use of CAC Score for CHD Prediction: Design
|
|
S-Z
|
|
|
|
|
|
San Luigi Gonzaga Diabetes Study: Design
|
|
San Luigi Gonzaga Diabetes Study: Results
|
|
SANDS: Study Design
|
|
SANDS: Change in CIMT with Aggressive vs Standard Therapy
|
|
SHEEP: Risk Factors for Nonfatal MI in Men and Women
|
|
WISE: Prevalence of Angiographic CAD Based on BMI, Metabolic Status
|
|
Cholesterol and CHD: Seven Countries Study
|
|
Effect of Lifestyle Changes on Angiographic CAD
|
|
WOSCOPS: Effects of Lipid Lowering on Coronary Events in Primary Prevention Trial in Men
|
|
WOSCOPS: Relation of Baseline LDL-C to Event Rate
|
|
WOSCOPS: Relation of Baseline HDL-C to Event Rate
|
|
WOSCOPS: Relation Between Quintiles of LDL-C Reduction and CHD Events
|
|
WHI trial of Estrogen, Progestin Ended
|
|
Outcomes in WHI Trial of Estrogen, Progestin
|
|
WHI: CHD, Stroke Outcomes in Estrogen-Alone Arm
|
|
Treating to New Targets: Mean Lipid Levels
|
|
TNT: Hazard Ratios for the Primary Outcome
|
|
TNT: Hazard Ratios for Primary Outcome Components
|
|
TNT: Hazard Ratios for Secondary Outcomes
|
|
Relationship Between LDL-C and Event Rates in TNT and Other Statin Trials
|
|
TNT: Safety Profile
|
|
TROPHY: Analysis of New-Onset Hypertension
|
|
SPARCL Primary Outcome: Fatal or Nonfatal Stroke
|
|
Prevalence of Macrovascular Disease and CHD According to Quintiles of Fasting C-Peptide
|
|
Swedish Register Study Design and Baseline Characteristics
|
|
Swedish Register Study: Early Statin Treatment Improves Post-AMI Survival Rates
|
|
Swedish Register Study: Implications for Early Statin Treatment
|
|
STELLAR: Percent Change in LDL-C From Baseline
|
|
STELLAR: Percent Change in HDL-C From Baseline
|
|
STELLAR: Percent of Patients at NCEP ATP III LDL-C Goal (6-Week Data)
|
|
The Strong Heart Study: Differences in CVD Risk Factors by Diabetic Status in Men and Women
|
|
WESDR: Hyperglycemia and the Risk for Vascular Complications in Older-Onset Diabetes
|
|
WESDR: Hyperglycemia and the Risk for Cause-Specific CVD Mortality
|
|
UKPDS: Intensive Blood-Glucose vs Conventional Treatment in Patients With Type 2 Diabetes
|
|
UKPDS: Tight Blood Pressure Control vs Less Tight Control in Patients With Type 2 Diabetes
|
|
WOSCOPS: Development of Type 2 Diabetes
|
|
Strong Heart Study: Non–HDL-C as CVD Risk Predictor in Patients With Diabetes
|
|
Strong Heart Study: Non–HDL-C Compared With Other CVD Risk Predictors
|
|
Steno-2: Effect of Therapies on Selected Risk Factors
|
|
Steno-2 Study: Primary Composite End Point or Surgery for PAD
|
SEACOAST: Combination Therapy for Increased Non–HDL-C
Primary Endpoint
|
|
Trends in CHD Risk Among Adults With Diabetes: Design
|
|
Trends in CHD Risk Among Adults With Diabetes: Results
|
|
Women’s Health Study: Association of Fasting and Nonfasting Lipids With CVD
|
|
SEARCH: Rate of Major Vascular Events
|
|
Look AHEAD: Design
|
Look AHEAD: Interventions
|
Look AHEAD: Change in Body Weight Across BMI Groups
|
Look AHEAD: Change in Fitness Levels Across BMI Groups
|
Look AHEAD: Additional Results
|
San Luigi Gonzaga Diabetes Study: Design
|
San Luigi Gonzaga Diabetes Study: Results
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Design
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Results
|
Trends in CHD Risk Among Adults With Diabetes: Design
|
Trends in CHD Risk Among Adults With Diabetes: Results
|
Dialogues in Dyslipidemia
|
|
Nonpharmacologic Therapies
|
|
Diet
|
|
|
|
|
|
Look AHEAD: Design
|
|
Look AHEAD: Interventions
|
|
Look AHEAD: Change in Body Weight Across BMI Groups
|
|
Look AHEAD: Change in Fitness Levels Across BMI Groups
|
|
Look AHEAD: Additional Results
|
|
Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes
|
|
Finnish Diabetes Prevention Study: Success in Achieving Treatment Goals at 1 Year
|
|
Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes
|
|
Diabetes Prevention Program: Study Design
|
|
Diabetes Prevention Program
|
|
AVERT: Overview of Study Procedures
|
|
L-TAP: Patient Success in Achieving Target LDL-C Levels
|
|
Lyon Diet Heart Study: Cumulative Survival Without Cardiac Death and Nonfatal MI
|
|
Effect of Lifestyle Changes on Angiographic CAD
|
|
Outcomes in WHI Trial of Estrogen, Progestin
|
|
Trans-Fatty Acid Intake and Relative Risk for CHD
|
|
Lipid Lowering and Plaque Regression: Monotherapy Studies
|
|
Event Reduction in Angiographic Plaque Regression Trials
|
|
Effect of Cholesterol Lowering on Myocardial Ischemia
|
|
Angiographically Inapparent Atheroma
|
|
ATP III: Features Shared With ATP II
|
|
ATP III: Nutritional Components of the TLC Diet
|
|
ATP III: Additional Dietary Options for LDL-C Lowering
|
|
ATP III: Management of Elevated TG
|
|
Statin Advisory: Risk Factors for Statin-Associated Myopathy
|
|
ABCs of CVD Risk Management (cont.)
|
|
Two LC-HP Diets Compared With Conventional Recommendations
|
|
LC-HP Diets: Potential Adverse Effects
|
|
Low-Carb vs Low-Fat Diet in Obese Patients (1 Y)
|
|
Low-Carb vs Low-Fat Diet in Overweight Patients (24 wk)
|
|
Potential Mortality Reduction With Lifestyle/Dietary Changes
|
|
Fruit/Vegetable Consumption: Effects on Stroke Risk Reduction
|
|
Reduced Intake of Trans-Fatty Acids: Estimated Effects on CHD
|
|
Effects of Drug Therapy and Diet on Lipids
|
|
Wine Consumption and CHD
|
|
Impact on TG Following Dietary Restrictions
|
|
TG Metabolism in CHD: Studies in the Postprandial State
|
|
Nonpharmacological Approaches to TG Lowering
|
|
Benefits of Intensive Lifestyle Changes on TG Levels
|
|
Effects of Lipid Lowering on Endothelial Function: Hypercholesterolemic Patients
|
|
Effects of Lipid-Lowering Therapy on Myocardial Perfusion in CHD Patients
|
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Results
|
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Additional Results at Year 1
|
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Design
|
|
ADA Nutrition Strategies, Interventions for Improved Metabolic Control
|
|
Impact of Diet and Physical Activity on Weight Loss, Cardiometabolic Risk Factors
|
|
Impact of Diet and Physical Activity on Weight Loss, Cardiometabolic Risk Factors: Results
|
|
Impact of Intense Exercise and Moderate Caloric Restriction on CV Risk Factors: Design
|
|
Impact of Intense Exercise and Moderate Caloric Restriction on CV Risk Factors: Results
|
|
Exercise
|
|
|
|
|
|
Look AHEAD: Design
|
|
Look AHEAD: Interventions
|
|
Look AHEAD: Change in Body Weight Across BMI Groups
|
|
Look AHEAD: Change in Fitness Levels Across BMI Groups
|
|
Look AHEAD: Additional Results
|
|
Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes
|
|
Finnish Diabetes Prevention Study: Success in Achieving Treatment Goals at 1 Year
|
|
Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes
|
|
Diabetes Prevention Program: Study Design
|
|
Diabetes Prevention Program
|
|
Effect of Lifestyle Changes on Angiographic CAD
|
|
Treatment Options for Peripheral Arterial Disease
|
|
Treatment Options for Peripheral Arterial Disease (cont)
|
|
Lipid Lowering and Plaque Regression: Monotherapy Studies
|
|
Angiographically Inapparent Atheroma
|
|
ATP III: Features Shared With ATP II
|
|
ATP III: Management of Elevated TG
|
|
ABCs of CVD Risk Management (cont.)
|
|
Potential Mortality Reduction With Lifestyle/Dietary Changes
|
|
Effects of Drug Therapy and Diet on Lipids
|
|
Nonpharmacological Approaches to TG Lowering
|
|
Benefits of Intensive Lifestyle Changes on TG Levels
|
|
Prevalence and CVD Correlates of Low Cardiorespiratory Fitness
|
|
Metabolic Syndrome and Cardiorespiratory Fitness
|
|
ADA Nutrition Strategies, Interventions for Improved Metabolic Control
|
|
Impact of Diet and Physical Activity on Weight Loss, Cardiometabolic Risk Factors
|
|
Impact of Diet and Physical Activity on Weight Loss, Cardiometabolic Risk Factors: Results
|
|
Impact of Intense Exercise and Moderate Caloric Restriction on CV Risk Factors: Results
|
|
Other
|
|
|
|
|
|
AVERT: Study Design and Inclusion Criteria
|
|
AVERT: Major Exclusion Criteria
|
|
AVERT: Overview of Study Procedures
|
|
AVERT: Primary Efficacy Assessment
|
|
AVERT: Secondary Efficacy Assessments
|
|
AVERT: Baseline Patient Characteristics
|
|
AVERT: Ischemic Events
|
|
AVERT: Time to First Ischemic Event
|
|
AVERT: Summary of Lipid Parameters
|
|
AVERT: Incidence of First Ischemic Event by Time
|
|
AVERT: Safety Evaluation
|
|
AVERT: Conclusions
|
|
Heart Protection Study (HPS): Elibigility
|
|
HPS: Design and Interventions
|
|
Heart Protection Study (HPS): End Points for Antioxidant Vitamin Supplementation
|
|
HPS: Effects of Antioxidant Vitamins on Cause-Specific Mortality
|
|
HPS: Effects of Antioxidant Vitamins on First Major Vascular Event
|
|
HPS: Effects of Antioxidant Vitamins on Vascular Events by Year
|
|
HPS: Effects of Antioxidant Vitamins on Vascular Events by LDL-C
|
|
HATS: Lipid Levels Before and During Treatment
|
|
HATS: Percent Change in Stenosis
|
|
JNC 7: Classification and Management of Blood Pressure for Adults
|
|
Treatment Options for Peripheral Arterial Disease
|
|
ABCs of CVD Risk Management (cont.)
|
|
Nonpharmacological Approaches to TG Lowering
|
|
Intensive Lifestyle Interventions: Effects on Endothelial Function and Inflammatory Markers Design
|
|
Intensive Lifestyle Interventions: Effects on Endothelial Function and Inflammatory Markers Results
|
|
SU.FOL.OM-3: Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD—Design
|
|
Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD: Primary Endpoint
|
|
Look AHEAD: Design
|
Look AHEAD: Interventions
|
Look AHEAD: Change in Body Weight Across BMI Groups
|
Look AHEAD: Change in Fitness Levels Across BMI Groups
|
Look AHEAD: Additional Results
|
Impact of Diet and Physical Activity on Weight Loss, Cardiometabolic Risk Factors
|
Impact of Diet and Physical Activity on Weight Loss, Cardiometabolic Risk Factors: Results
|
SU.FOL.OM-3: Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD—Design
|
Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD: Primary Endpoint
|
Impact of Intense Exercise and Moderate Caloric Restriction on CV Risk Factors: Design
|
Impact of Intense Exercise and Moderate Caloric Restriction on CV Risk Factors: Results
|
Pharmacologic Therapies: Blood Pressure Management
|
|
Blood Pressure Management
|
|
|
|
|
|
ALLHAT-LLT: All-Cause Mortality
|
|
ALLHAT-LLT: Comparison to Other Large, Long-Term Statin Trials
|
|
ASCOT–LLA: Study Design
|
|
ASCOT-LLA: Primary End Point
|
|
ASCOT-LLA: Primary End Point in Subgroups
|
|
ACCORD BP: Effects of Intensive BP_Control on Type 2 Diabetes
|
|
Primary CHD Prevention in Patients With Type 2 Diabetes: The Helsinki Heart Study
|
|
TROPHY: Analysis of New-Onset Hypertension
|
|
UKPDS: Tight Blood Pressure Control vs Less Tight Control in Patients With Type 2 Diabetes
|
|
Angiographically Inapparent Atheroma
|
|
JNC 7: Treatment Algorithm for Hypertension
|
|
ABCs of CVD Risk Management
|
|
HF Rates in Hypersensitive Blacks and Non-Blacks: ALLHAT
|
|
Safety and Tolerability of Monotherapy, Combination BP Therapy
|
|
ASCOT-LLA: Incidence for Total CVD Events/Procedures in Patients With Diabetes
|
|
Common Drug Treatments for Patients With Metabolic Syndrome
|
|
Effect of Monotherapy, Combination Therapy on Blood Pressures
|
|
Renin-Angiotensin Blockade: Beyond BP Lowering
|
|
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye: Substudy of ACCORD
|
|
ACCORD Eye: Progression of Diabetic Retinopathy By Treatment Group at Year 4
|
|
ACCORD Eye: Moderate Vision Loss By Treatment Group at Year 4
|
|
ARB Use and Risk of MI, CV Events (1 of 2)
|
|
ARB Use and Risk of MI, CV Events (2 of 2)
|
|
CLINICAL TRIALS: A-F
|
|
A-HeFT: First HF Trial in African-Americans
|
|
A-HeFT: 43% Decrease in Mortality
|
|
A-HeFT: Components of Composite Score
|
|
A-HeFT: Conclusions
|
|
AASK: Relative Risk Reduction With Ramipril vs Amlodipine
|
|
AASK: Renoprotective Effects of Ramipril in Hypertension
|
|
ADHERE: Long-Term Medication Use
|
|
ALLHAT: Design, Hypothesis, and Baseline Demographics
|
|
ALLHAT: Blood Pressure Results by Treatment Group
|
|
ALLHAT: Cumulative Event Rates for Primary Outcome
|
|
ALLHAT: Cumulative Event Rates for Heart Failure
|
|
ALLHAT: Lisinopril vs Chlorthalidone in Blacks
|
|
ALLHAT: Lisinopril vs Chlorthalidone in Nonblacks
|
|
ALLHAT: Amlodipine vs Chlorthalidone in Blacks
|
|
ALLHAT: Amlodipine vs Chlorthalidone in Nonblacks
|
|
ALLHAT: Heart Failure Rate for Blacks
|
|
ALLHAT: Heart Failure Rate for Nonblacks
|
|
ALLHAT: Angioedema in Blacks vs Nonblacks
|
|
ALLHAT: Effect of Antihypertensive Class on New-Onset Diabetes
|
|
ALLHAT: Fasting Glucose by Treatment Group
|
|
ALLHAT: Reduced Diabetes Risk With Lisinopril
|
|
BP-Lowering Treatment Trialists: Heart Failure
|
|
CALM: Renoprotection With Candesartan vs Lisinopril in Type 2 Diabetes
|
|
CAMELOT: Design, Hypothesis, and Baseline Characteristics
|
|
CAMELOT: Primary Endpoint (1 of 2)
|
|
CAMELOT: Primary Endpoint (2 of 2)
|
|
CHARM: ARBs in Heart Failure
|
|
CHARM-Overall: Design, Hypothesis, and Baseline Characteristics
|
|
CHARM-Overall: Primary Endpoint (CV and Non-CV Death)
|
|
CHARM-Alternative: Primary Endpoint
|
|
DECODE: IFG and IGT Are Associated With Increased Mortality Rate
|
|
DPP: Study Design
|
|
DPP: Incidence of Type 2 Diabetes
|
|
DPP: Fasting Plasma Glucose Over Time
|
|
East-West Study: 7-Year Incidence of Fatal and Nonfatal MI in Type 2 Diabetes and CHD
|
|
EPHESUS: Death Rate From CV Causes or Hospitalization for CV Events
|
|
EUROPA: Design, Hypothesis, and Baseline Demographics
|
|
EUROPA: Frequency of Primary Endpoints
|
|
CLINICAL TRIALS: G-L
|
|
HOPE: Design, Hypothesis, and Baseline Demographics
|
|
HOPE: Composite Outcome Results
|
|
HOPE: Rate of Developing Heart Failure
|
|
HOPE: Risk of Cardiovascular Events According to Microalbuminuria and Diabetes Status
|
|
HOPE: Risk Reduction With Ramipril
|
|
IDNT: Renoprotective Effects of Irbesartan in Type 2 Diabetes
|
|
IDNT: Effects of Irbesartan vs Amlopidine in Diabetic Nephropathy—Design
|
|
IDNT: Effects of Irbesartan vs Amlopidine in Diabetic Nephropathy—Results
|
|
IRAS: CVD Risk Factors Are Also Risk Factors for Type 2 Diabetes
|
|
IRMA 2: Renoprotective Effects of Irbesartan in Type 2 Diabetes
|
|
LIFE: Design, Hypothesis, and Baseline Characteristics
|
|
LIFE: Primary Composite Endpoint
|
|
LIFE: Fatal and Nonfatal Stroke
|
|
LIFE: New-Onset Diabetes
|
|
CLINICAL TRIALS: M-R
|
|
Meta-Analysis: CHD Events in Type 2 Diabetes—Primary-Prevention Lipid Lowering
|
|
Meta-Analysis: Effects of RAS Inhibition on Risk of New-Onset Diabetes
|
|
Meta-Analysis: Overlap in Racial Response to Antihypertensives
|
|
MICRO-HOPE: ACEI Reduces Risk of Nephropathy and CHFin Patients With Type 2 Diabetes
|
|
PEACE: Design, Hypothesis, and Baseline Demographics
|
|
PEACE: CHF, Stroke, and All-Cause Mortality
|
|
PIUMA: Cumulative Risk and Metabolic Syndrome Characteristics
|
|
PREMIER: Study Design
|
|
PREMIER: Lifestyle Modification Success Rates
|
|
PREMIER: Study Results
|
|
RENAAL: Design, Hypothesis, and Baseline Demographics
|
|
RENAAL: Risk Reduction With Losartan—Design
|
|
RENAAL: Reduced Heart Failure With Losartan
|
|
RENAAL: Impact of Losartan in Chronic Kidney Disease
|
|
RENAAL: Risk Reduction With Losartan—Results
|
|
CLINICAL TRIALS: S-Z
|
|
SHEP: Older Patients With ISH
|
|
Syst-China: Stepwise BP Treatment Improves Prognosis in Elderly Chinese
|
|
Syst-Eur: Older Patients With ISH
|
|
Syst-Eur: Older Patients With ISH
|
|
Val-HeFT: Design, Hypothesis, and Baseline Demographics
|
|
Val-HeFT: Primary Endpoint
|
|
Val-HeFT: Heart Failure Morbidity in Patients Not on ACEI
|
|
VALIANT: Design, Hypothesis, and Baseline Demographics
|
|
VALIANT: Primary Endpoint Death from Any Cause
|
|
VALIANT: CV Mortality and Morbidity
|
|
VALIANT: Conclusions
|
|
VALUE: Design, Hypothesis, and Baseline Demographics
|
|
VALUE: Systolic Blood Pressure in Study
|
|
VALUE: Incidence of New-Onset Diabetes
|
|
VALUE: Time to First Cardiac Event
|
|
COMORBIDITIES: CVD/CHD
|
|
Albuminuria as Independent Risk Factor for Mortality in Type 2 Diabetes
|
|
ALLHAT: Cumulative Event Rates for Primary Outcome
|
|
ALLHAT: Cumulative Event Rates for Heart Failure
|
|
ALLHAT: Lisinopril vs Chlorthalidone in Blacks
|
|
ALLHAT: Lisinopril vs Chlorthalidone in Nonblacks
|
|
ALLHAT: Amlodipine vs Chlorthalidone in Blacks
|
|
ALLHAT: Amlodipine vs Chlorthalidone in Nonblacks
|
|
ALLHAT: Heart Failure Rate for Blacks
|
|
ALLHAT: Heart Failure Rate for Nonblacks
|
|
ATP III: Management of Diabetic Dyslipidemia
|
|
ATP III: The Metabolic Syndrome Diagnosis Established When ≥3 Risk Factors Are Present
|
|
BP-Lowering Treatment Trialists: Heart Failure
|
|
CAMELOT: Primary Endpoint (1 of 2)
|
|
CAMELOT: Primary Endpoint (2 of 2)
|
|
CHARM-Overall: Primary Endpoint (CV and Non-CV Death)
|
|
CHARM-Alternative: Primary Endpoint
|
|
Comparisons of ARB-Based Regimens With Control Regimens in HTN
|
|
Compelling Indications for Hypertension Drug Classes (1 of 2)
|
|
Compelling Indications for Hypertension Drug Classes (2 of 2)
|
|
CVD Risk Increases With BMI in Asia-Pacific Region
|
|
CVD Risk Reduction From Tight Control of BP and Glucose in Type 2 Diabetes
|
|
Diabetes: The Most Common Cause of ESRD
|
|
Diabetes and CVD
|
|
East-West Study: 7-Year Incidence of Fatal and Nonfatal MI in Type 2 Diabetes and CHD
|
|
Elevated Risk of CVD Prior to Clinical Diagnosis of Type 2 Diabetes
|
|
EPHESUS: Death Rate From CV Causesor Hospitalization for CV Events
|
|
HOPE: Composite Outcome* Results
|
|
HOPE:Rate of Developing Heart Failure
|
|
HOPE: Risk of Cardiovascular Events According to Microalbuminuria and Diabetes Status
|
|
IRAS: CVD Risk Factors Are Also Risk Factors for Type 2 Diabetes
|
|
LIFE: Primary Composite Endpoint
|
|
LIFE: Fatal and Nonfatal Stroke
|
|
MERIT-HF: Subgroup Analysis by Race
|
|
Meta-Analysis: CHD Events in Type 2 Diabetes—Primary-Prevention Lipid Lowering
|
|
Microalbuminuria Predicts CV Risk at Levels Below Current Definition
|
|
Non-Obese Asian-Indians With High CVD Risk
|
|
PEACE: CHF, Stroke, and All-Cause Mortality
|
|
PIUMA: Cumulative Risk and Metabolic Syndrome Characteristics
|
|
Relationship Between Estimated GFR and Cardiovascular Outcome
|
|
RENAAL: Reduced Heart Failure With Losartan
|
|
SHEP: Older Patients With ISH
|
|
Stroke Mortality Rate vs Usual Blood Pressure
|
|
Syst-Eur: Older Patients With ISH
|
|
Val-HeFT: Primary Endpoint
|
|
VALIANT: Conclusions
|
|
COMORBIDITIES: DIABETES/RENOPROTECTION
|
|
AASK: Renoprotective Effects of Ramipril in Hypertension
|
|
ALLHAT: Effect of Antihypertensive Class on New-Onset Diabetes
|
|
ALLHAT: Fasting Glucose by Treatment Group
|
|
Compelling Indications for Hypertension Drug Classes
|
|
Diabetes and Hypertension
|
|
Elevated Risk of CVD Prior to Clinical Diagnosis of Type 2 Diabetes
|
|
HOPE: Risk of Cardiovascular Events According to Microalbuminuria and Diabetes Status
|
|
IDNT: Effects of Irbesartan vs Amlopidine in Diabetic Nephropathy—Proteinuria Results
|
|
IRAS: CVD Risk Factors Are Also Risk Factors for Type 2 Diabetes
|
|
IRMA 2: Renoprotective Effects of Irbesartan in Type 2 Diabetes
|
|
MARVAL: Risk Reduction With Valsartan vs Amlopidine
|
|
PIUMA: Cumulative Risk and Metabolic Syndrome Characteristics
|
|
GUIDELINES AND CLASSIFICATIONS: HYPERTENSION
|
|
Classification of Heart Failure: ACC/AHA Stage vs NYHA Class
|
|
DASH Diet
|
|
DASH-Sodium Study: Effect on Blood Pressure
|
|
ISHIB: Hypertension Treatment in African Americans
|
|
ISHIB Recommendations for African-Americans With High BP
|
|
JNC 7: Hypertension Treatment Algorithm
|
|
JNC 7: Lifestyle Modifications to Manage Hypertension
|
|
Recommended Treatment of Hypertension in Diabetes
|
|
GUIDELINES AND CLASSIFICATIONS: GLOBAL RISK ASSESSMENT
|
|
ADA: Recommended Treatment of Hypertension
|
|
ADA: Diagnostic Criteria for Diabetes, IFG, IGT
|
|
Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines
|
|
K/DOQI Guidelines: Estimating GFR
|
|
Microalbuminuria and Macroalbuminuria
|
|
National Kidney Foundation: Stages and Prevalence of CKD (Age >20 Years)
|
|
Risk Factors for Proteinuria in CKD
|
|
Screening for Proteinuria
|
|
NONPHARMACOLOGIC THERAPIES
|
|
PREMIER: Lifestyle Modification Success Rates
|
|
Women’s Health Initiative: Total Energy Expenditure From Walking
|
|
PHARMACOLOGIC THERAPIES
|
|
ACE-Inhibitors Not For Everyone
|
|
Clinical Trials of ARBs in Older HF Patients
|
|
Combination Therapy Often Required to Reach JNC Goals
|
|
Effect of Antihypertensive Drug Treatment on Cardiovascular Events
|
|
Polypharmacy and Aging
|
|
SPECIAL POPULATIONS
|
|
A-HeFT: First HF Trial in African-Americans
|
|
A-HeFT: 43% Decrease in Mortality
|
|
A-HeFT: Components of Composite Score
|
|
A-HeFT: Conclusions
|
|
AASK: Overview
|
|
AASK: Relative Risk Reduction With Ramipril vs Amlodipine
|
|
ALLHAT: Lisinopril vs Chlorthalidone in Blacks
|
|
ALLHAT: Amlodipine vs Chlorthalidone in Blacks
|
|
ALLHAT: Heart Failure Rate for Blacks
|
|
ALLHAT: Angioedema in Blacks vs Nonblacks
|
|
Amlodipine vs Enalapril in Hypertensive Chinese Patients
|
|
Effects of Beta-Blocker in HF: African-Americans
|
|
Effect of Carvedilol in African-American Patients With HF
|
|
Higher CRP Concentrations in Asian-Indians Living in the US
|
|
JNC 7: Considerations for Special Populations
|
|
STATISTICS
|
|
Cardiovascular Disease Continuum
|
|
Death Rates From Hypertension
|
|
Forecasted Increases in Worldwide Hypertension Prevalence
|
|
From Risk Factors to Heart Failure
|
|
HF in African-Americans
|
|
HF Incidence in African-Americans by Age, Gender
|
|
Heart Failure Facts
|
|
Hypertension Awareness, Treatment, and Control: US 1976 to 2000
|
|
Hypertension Challenges in the Elderly
|
|
Hypertension Facts
|
|
Hypertension in African-Americans
|
|
Impact of High-Normal BP on CVD Risk in Women: Framingham Study
|
|
Kidney Disease and Diabetes
|
|
Lower BP Key to a Healthier Life
|
|
Overweight/Obesity: Mortality
|
|
Population-Attributable Risk* for Heart Failure Development
|
|
Role of Waist Circumference in Assessing Risk
|
|
Smoking: Mortality
|
|
Time-to-Benefit of Smoking Cessation After Last Cigarette
|
|
US Adults With HTN by Sex, Race, Ethnicity: NHANES 1988-1994 to 1999-2000
|
|
US Prevalence of Cardiovascular Diseases
|
|
Prevalence of Hypertension: NHANES, 1999–2000
|
|
Hypertension Largely Uncontrolled Across Ethnic Groups
|
|
Race/Ethnicity and HBP
|
|
Hypertension in African Americans
|
|
Greater RR of Comorbid Conditions, Events in Blacks vs Whites
|
|
Hypertension in African Americans
|
|
Keys to Treating Hypertension in African-American Patients
|
|
In African Americans, Some Barriers to Hypertension Control Are Patient-Related
|
|
In African Americans, Some Barriers to Hypertension Control Are Physician-Related
|
|
RAS Blockade in Blacks
|
|
ALLHAT: Stroke in Different Subgroups
|
|
AASK: Results
|
|
Blacks in LIFE
|
|
HTN in Hispanic Americans
|
|
HTN in South Asians
|
|
HTN in East Asians and Native Hawaiians
|
|
JNC 7: Considerations for Special Populations
|
|
Hypertension in Men: More Prevalent in Blacks
|
|
Hypertension in Women:More Prevalent in Blacks
|
|
Characteristics of Hypertension in African Americans
|
|
Blacks Have Higher CHD, Stroke Mortality Rates
|
|
Hypertension in Men: Prevalence in Hispanics Versus Whites
|
|
Hypertension in Women: Prevalence in Hispanics Versus Whites
|
|
Lower Vs Standard BP Targets: Reductions in Morbidity and Mortality?
|
|
Comparison of CV Outcomes for First-Line Hypertension Treatments
|
|
Tight Vs Usual Control of Systolic BP Among Non-Diabetic Subjects With Hypertension
|
|
Effect of Dietary and Lifestyle Factors on Hypertension Among Women: Design
|
|
Association Between New-Onset Diabetes and Antihypertensive Therapy
|
|
Effect of Dietary and Lifestyle Factors on Hypertension Among Women: Results
|
|
ARB Use and Risk of MI, CV Events (1 of 2)
|
ARB Use and Risk of MI, CV Events (2 of 2)
|
Pharmacologic Therapies: Diabetes Management
|
|
Diabetes Management
|
|
|
|
|
|
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Design
|
|
Effects of Liraglutide and Insulin on Cardiovascular Disease Risk Factors
|
|
Liraglutide Effect on Cardiovascular Disease: Results Among Patients Switched from Exenatide
|
|
Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes
|
|
Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes
|
|
Diabetes Prevention Program: Study Design
|
|
Diabetes Prevention Program
|
|
DREAM: Primary Outcome of New Onset Diabetes or Death
|
|
ASCOT-LLA: Primary End Point in Subgroups
|
|
FIELD: Fenofibrate Effect on Lipids
|
|
DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes
|
|
DAIS: Mean Baseline Lipoprotein Levels
|
|
DAIS: Interim Lipid Results in Patients With Type 2 Diabetes
|
|
DAIS: Final Results in Patients With Types 2 Diabetes
|
|
Framingham Heart Study 30-Year Follow-Up: CVD Events in Patients With Diabetes (Ages 35-64)
|
|
Secondary Prevention: CHD Risk Reduction in the 4S Subgroup of Patients WIth Diabetes
|
|
4S: Total Mortality Reduction in a Subgroup of Patients With Diabetes
|
|
4S: Major CHD Event Reduction in a Subgroup of Patients With Diabetes
|
|
4S: Treatment Benefit in Subgroup With Impaired Fasting Glucose (FG 110-125 mg/dL)
|
|
CARE: Reduction of Coronary Events in Patients With Diabetes
|
|
CARE: Major Coronary Events in the Diabetic Subgroup
|
|
ARIC: CHD Events, CVD Mortality With/Without MI or Diabetes
|
|
Collaborative Atorvastatin Diabetes Study (CARDS): Results Summary
|
|
Collaborative Atorvastatin Diabetes Study (CARDS): Major CVD Events
|
|
CARDS: Effect of Treatment on Primary and Secondary End Points
|
|
CARDS: Effect of Treatment on Primary End Point by Lipid Level
|
|
HOPE Study: Outcomes in Patients With Diabetes
|
|
HPS Substudy: First Major Coronary Event and Stroke by Prior to Diabetes Status
|
|
HPS Substudy: First Major Vascular Event by LDL-C and Prior Diabetes Status
|
|
HPS Diabetes Substudy: Absolute Effects on 5-Year Rates of First Major Vascular Event
|
|
PROactive: Primary and Main Secondary Endpoint Results
|
|
PROactive Subanalysis: Time to Fatal or Nonfatal Stroke in Patients With vs Without Previous Stroke
|
|
TNT: Intensive Atorvastatin Treatment Reduces Cardiovascular Events in Patients With CHD and Diabetes
|
|
SPARCL: First Events
|
|
ADA/AHA: Different Approaches to Primary Prevention of CVD in Patients With Type 2 Diabetes
|
|
ADA Treatment Recommendations for Hypertension and Nephropathy
|
|
ADA Targets for Lipids in Type 2 Diabetes
|
|
ADA Recommendations for Aspirin Therapy in Diabetes
|
|
ADA Guidelines for Treatment of Older Adults With Diabetes
|
|
Treatment of Lipid Disorders in Patients With Diabetes
|
|
Common Drug Treatments for Patients With Metabolic Syndrome
|
|
Odds of CVD by Disease Condition and CRP Level
|
|
Non–HDL-C as a Predictor of Risk for CHD in Diabetes
|
|
Global Impact of Hyperglycemia: Ischemic Heart Disease and Stroke Mortality
|
|
Diabetes Is Undertreated Even When Atherosclerosis Present
|
|
Cardiovascular Mortality in Patients With Coronary Artery Disease by BMI
|
|
PROactive 10 Substudy: Time to First Event from MACE Endpointa
|
|
PROactive 10 Substudy: Time to CV Death, Nonfatal MIa, Nonfatal Stroke
|
|
PROactive 10 Substudy: Time to All-Cause Mortality, Nonfatal MIa, Nonfatal Stroke, or ACS
|
|
PROSPER: Association of Leptin With Diabetes
|
|
PROSPER: Association of Leptin With CVD
|
|
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye: Substudy of ACCORD
|
|
ACCORD Eye: Progression of Diabetic Retinopathy By Treatment Group at Year 4
|
|
ACCORD Eye: Moderate Vision Loss By Treatment Group at Year 4
|
|
Liraglutide Vs Sigagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: Design
|
|
Liraglutide Vs Sigagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: A1C Reduction
|
|
CANOE: Low-Dose Combination Therapy With Rosiglitazone Plus Metformin for Diabetes Prevention
|
|
CANOE: Development of New-Onset Diabetes With Low-Dose Combination Therapy Vs Placebo
|
|
LOADD: Primary Endpoint—Difference in A1C at 6 Months
|
|
PROSPER: Association of Leptin With CVD
|
|
PROSPER: Association of Leptin With Diabetes
|
|
Impact of Higher Heart Rate on Development of Cardiometabolic Risk Factors After 20 Years
|
|
RECORD: Study Design
|
|
RECORD: CV Death and Hospitalization
|
|
RECORD: Time to Primary Endpoint
|
|
RECORD: Bone Fracture Rates in Upper and Distal Lower Limbs
|
|
RECORD: Conclusion
|
|
CVD Mortality Risk Rate Among Men With MetSyn and Diabetes, Alone and in Combination
|
|
Hazard Ratios of CVD Mortality Among Men with MetSyn and Diabetes, Alone and in Combination
|
|
ADA Nutrition Strategies, Interventions for Improved Metabolic Control
|
|
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Design
|
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Results
|
Effects of Liraglutide and Insulin on Cardiovascular Disease Risk Factors
|
Liraglutide Effect on Cardiovascular Disease: Results Among Patients Switched from Exenatide
|
Pharmacologic Therapies: Lipid Management
|
|
Bile-Acid Sequestrants
|
|
|
|
|
|
L-TAP: Patient Success in Achieving Target LDL-C Levels
|
|
L-CAD: Effect of Intensive Therapy Post-ACS on Lipid Values
|
|
L-CAD: Comparison of End Points, Change in Lumen Diameters
|
|
Post-CABG: Impact of Aggressive vs Moderate Lowering of LDL-C on Atherosclerosis
|
|
Post-CABG Study: Aggressive vs Moderate Treatment
|
|
Post-CABG: End Points, Results, Conclusions
|
|
Post-CABG Angiographic Outcomes
|
|
Post-CABG: Event Rates by Cholesterol Group
|
|
Post-CABG: Aggressive LDL-C Lowering Delays Progression of Atherosclerosis in Women, Elderly, and Patients With Selected CHD Risk Factors
|
|
ATP III: Management of Very High LDL-C
|
|
Effects of Lipid Lowering on Endothelial Function: Hypercholesterolemic Patients
|
|
Effects of Lipid-Lowering Therapy on Myocardial Perfusion in CHD Patients
|
|
Metabolic Effects of Lipid-Lowering Agents on Lipoproteins
|
|
Colesevelam, Atorvastatin—Effects on Lipids
|
|
Common Drug Treatments for Patients With Metabolic Syndrome
|
|
Cholesterol-Absorption Inhibitors
|
|
|
|
|
|
Common Drug Treatments for Patients With Metabolic Syndrome
|
|
Effect of Ezetimibe Monotherapy on Lipids in Patients With Primary Hypercholesterolemia
|
|
Effect of Ezetimibe + Statin Therapy on Lipids in Patients with Primary Hypercholesterolemia
|
|
Effect of Ezetimibe + Atorvastatin on Lipids in Primary Hypercholesterolemia
|
|
Effect of Ezetimibe + Simvastatin on Lipids in Primary Hypercholesterolemia
|
|
Effect of Ezetimibe + Lovastatin on Lipids in Primary Hypercholesterolemia
|
|
Fibric Acids
|
|
|
|
|
|
FIELD: Fenofibrate Effect on Lipids
|
|
DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes
|
|
DAIS: Interim Lipid Results in Patients With Type 2 Diabetes
|
|
DAIS: Final Results in Patients With Types 2 Diabetes
|
|
DIACOR Substudy: Effects of Simvastatin and/or Fenofibrate on Lipoprotein Subparticles
|
|
DIACOR Substudy: Level of LDL Pattern B at Baseline and Week 12
|
|
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
|
|
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
|
|
L-TAP: Patient Success in Achieving Target LDL-C Levels
|
|
Fasting TG and Risk for CHD: Helsinki Heart Study
|
|
HIT: Favorable Effects of Fibrate on CVD Events in CHD Patients With Isolated Low HDL-C
|
|
Primary CHD Prevention in Patients With Type 2 Diabetes: The Helsinki Heart Study
|
|
Fasting TG and Risk for CHD Death: Paris Prospective Study
|
|
Lipid Lowering and Plaque Regression: Monotherapy Studies
|
|
ATP III: Management of Elevated TG
|
|
Statin Advisory: Risk Factors for Statin-Associated Myopathy
|
|
Treatment of Lipid Disorders in Patients With Diabetes
|
|
Metabolic Effects of Lipid-Lowering Agents on Lipoproteins
|
|
Colesevelam, Atorvastatin—Effects on Lipids
|
|
Common Drug Treatments for Patients With Metabolic Syndrome
|
|
Clinical Benefits of Cholesterol Reduction
|
|
ATP III: Management of Low HDL-C
|
|
Lipid Lowering and Plaque Regression: Combination Therapy Studies
|
|
MI Prevention With Bezafibrate in Metabolic Syndrome
|
|
Incidence of Myopathy in 3 UK Cohorts
|
|
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye: Substudy of ACCORD
|
|
ACCORD Eye: Progression of Diabetic Retinopathy By Treatment Group at Year 4
|
|
ACCORD Eye: Moderate Vision Loss By Treatment Group at Year 4
|
|
Fibrates: Effects on Lipid Profiles and CV Events
|
|
Nicotinic Acid
|
|
|
|
|
|
L-TAP: Patient Success in Achieving Target LDL-C Levels
|
|
L-CAD: Effect of Intensive Therapy Post-ACS on Lipid Values
|
|
L-CAD: Comparison of End Points, Change in Lumen Diameters
|
|
HATS: Lipid Levels Before and During Treatment
|
|
HATS: Percent Change in Stenosis
|
SEACOAST: Combination Therapy for Increased Non–HDL-C
Primary Endpoint
|
|
ATP III: Management of Elevated TG
|
|
Statin Advisory: Risk Factors for Statin-Associated Myopathy
|
|
Treatment of Lipid Disorders in Patients With Diabetes
|
|
Metabolic Effects of Lipid-Lowering Agents on Lipoproteins
|
|
Common Drug Treatments for Patients With Metabolic Syndrome
|
|
ATP III: Management of Low HDL-C
|
|
Lipid Lowering and Plaque Regression: Combination Therapy Studies
|
|
Effect of Dual-Component E-R Niacin/Lovastatin on Lipids in Primary Hypercholesterolemia
|
|
ARBITER 6–Halts: Methods and Final Results
|
|
ARBITER 6–HALTS: Final Results
|
|
Omega-3 Fatty Acids
|
|
|
|
|
|
Omega-3 Concentrate: Effects on Lipids
|
|
Omega-3 Concentrate Plus Statin: Effects on TG
|
|
P-OM3 Plus Simvastatin: Study Design
|
|
P-OM3 Plus Simvastatin: Changes in Lipids and Lipoprotein Particles From Baseline
|
|
Omega-3 Acid Ethyl Esters in Addition to Statin Therapy: Effects on Lipoprotein Particle Concentrations
|
|
SU.FOL.OM-3: Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD—Design
|
|
Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD: Primary Endpoint
|
|
Statins
|
|
|
|
|
|
AFCAPS/TexCAPS: RR of Acute Coronary Events—LDL-C and Homocysteine
|
|
AFCAPS/TexCAPS: RR of Acute Coronary Events—TC: HDL-C Ratio and CRP Level
|
|
ACCESS: Change in LDL-C, Non–HDL-C in All Patients at 54 Weeks
|
|
4S: Effect of LDL-C Lowering on Coronary Events in Secondary Prevention Trial in Men and Women
|
|
4S: Findings From a Post Hoc Analysis
|
|
4S: Impact of Drug Therapy on Lipids and Lipoproteins in Older Adults With Hypercholesterolemia
|
|
4S: Reduction in Coronary Events and Revascularizations in Older Adults With Established CHD
|
|
4S: Survival of Major Coronary Events in Older Adults
|
|
4S: Clinical and Economic Benefits of Treatment Over 5-Yr Period
|
|
CARE: Effect of Lipid Lowering on Lipid Values and Coronary Events in CHD Patients With Average Cholesterol
|
|
CARE: Fatal CHD or Nonfatal MI (Primary End Point)
|
|
CARE: Secondary End Points
|
|
CARE: Findings From a Post Hoc Analysis
|
|
CARE: Impact of Drug Therapy on Lipids and Lipoproteins in Older Patients With MI
|
|
CARE: Reduction in Coronary Events, Revascularizations, and Stroke in Older Adults With MI and Average Cholesterol Levels
|
|
CARE: Incidence of Coronary Events in Younger Versus Older Patients
|
|
AFCAPS/TexCAPS: Primary End Point Event Rates Within Demographic and Risk Factor Subgroups
|
|
A to Z Trial: Primary End Point
|
|
A to Z Trial: Secondary End Points and Adverse Events
|
|
The CURVES Trial: A Comparison of LDL-C Lowering Among Statins
|
|
The CURVES Trial: Comparative LDL-C Reductions
|
|
ASAP: Study Design
|
|
ASAP: Cholesterol-Lowering Results
|
|
ASAP: Primary Parameter Change in Overall Carotid IMT
|
|
AVERT: Study Design and Inclusion Criteria
|
|
AVERT: Overview of Study Procedures
|
|
AVERT: Primary Efficacy Assessment
|
|
AVERT: Secondary Efficacy Assessments
|
|
AVERT: Baseline Patient Characteristics
|
|
AVERT: Ischemic Events
|
|
AVERT: Ischemic Events
|
|
AVERT: Time to First Ischemic Event
|
|
AVERT: Summary of Lipid Parameters
|
|
AVERT: Incidence of First Ischemic Event by Time
|
|
AVERT: Safety Evaluation
|
|
AVERT: Conclusions
|
|
ALLHAT-LLT: All-Cause Mortality
|
|
ALLHAT-LLT: Comparison to Other Large, Long-Term Statin Trials
|
|
ASCOT–LLA: Study Design
|
|
ASCOT-LLA: Primary End Point
|
|
ASCOT-LLA: Primary End Point in Subgroups
|
|
ASCOT-LLA: Secondary End Points
|
|
Collaborative Atorvastatin Diabetes Study (CARDS): Results Summary
|
|
Collaborative Atorvastatin Diabetes Study (CARDS): Major CVD Events
|
|
CARDS: Effect of Treatment on Primary and Secondary End Points
|
|
ASTEROID: High-Dose Statin Therapy–Effects on Atherosclerosis
|
|
ASTEROID: High-Dose Statin Therapy—Effects on LDL-C and HDL-C
|
|
ASTEROID: High-Dose Statin Therapy—Effects on Discrete Coronary Stenoses
|
|
METEOR: Effects of Statin Therapy on Low-Risk Patients—Primary Endpoint
|
|
METEOR: Effects of Statin Therapy on Low-Risk Patients—Secondary Endpoints
|
|
ENHANCE: Combination Therapy—Primary Outcome
|
|
ENHANCE: Combination Therapy—Effects on Lipoproteins
|
|
ACCORD: Study Design
|
|
DIACOR Substudy: Effects of Simvastatin and/or Fenofibrate on Lipoprotein Subparticles
|
|
DIACOR Substudy: Level of LDL Pattern B at Baseline and Week 12
|
|
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
|
|
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
|
|
L-TAP: Patient Success in Achieving Target LDL-C Levels
|
|
LIPID: Effect of Lipid Lowering on Lipid Values and Coronary Events in CHD Patients With Average Cholesterol
|
|
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Sex
|
|
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Diabetic Status
|
|
LIPID: Reduction in nonfatal MI and CHD Death Risk Stratified by Prerandomization Age
|
|
LIPID Trial Follow-Up: Cardiovascular Events Over 8 Years
|
|
LIPID Trial Follow-Up: Serious Adverse Events Over 8 Years
|
|
LCAS: Effect on Lipids between Baseline and End of Trial
|
|
LCAS: Primary End Point
|
|
LCAS: Effect of Treatment on Patients Experiencing Progression or Regression
|
|
LCAS: Conclusions
|
|
Heart Protection Study (HPS): Elibigility
|
|
HPS: Design and Interventions
|
|
HPS: End Points for Lipid Lowering
|
|
HPS: Effects of Simvastatin on Cause-Specific Mortality
|
|
HPS: Effects of Simvastatin on First major Vascular Event
|
|
HPS: Effects of Simvastatin on Vascular Events by Year
|
|
HPS: Effects of Simvastatin on Vascular Events by LDL-C
|
|
HPS: Absolute Risk Reductions
|
|
L-CAD: Effect of Intensive Therapy Post-ACS on Lipid Values
|
|
L-CAD: Comparison of End Points, Change in Lumen Diameters
|
|
HATS: Lipid Levels Before and During Treatment
|
|
HATS: Percent Change in Stenosis
|
|
IDEAL Study: Secondary End Points
|
|
IDEAL Study: Effect of Treatment on LDL-C
|
|
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Participant Profile
|
|
JUPITER: Study Design
|
|
PRINCE: Change in CRP Levels at 24 Weeks
|
|
Post-CABG: Impact of Aggressive vs Moderate Lowering of LDL-C on Atherosclerosis
|
|
Post-CABG Study: Aggressive vs Moderate Treatment
|
|
Post-CABG: End Points, Results, Conclusions
|
|
Post-CABG Angiographic Outcomes
|
|
Post-CABG: Event Rates by Cholesterol Group
|
|
Post-CABG: Aggressive LDL-C Lowering Delays Progression of Atherosclerosis in Women, Elderly, and Patients With Selected CHD Risk Factors
|
|
PROSPER: Primary Composite End Point Results CHD Death, Nonfatal MI, Fatal or Nonfatal Stroke
|
|
PROSPER: Secondary End Point Results
|
|
PROSPER: Rate of CHD-Related Death
|
|
MIRACL: Study Design
|
|
MIRACL: Major Exclusion Criteria
|
|
MIRACL: Outcome Measures
|
|
MIRACL: Baseline Patient Characteristics
|
|
MIRACL: Change in Lipid Levels
|
|
MIRACL: Time to First Ischemic Event
|
|
MIRACL: Occurrence of Primary Combined End Point
|
|
MIRACL: Fatal or Nonfatal Stroke
|
|
MIRACL: Conclusions and Implications
|
|
PRISM: Event Rate Curves
|
|
REVERSAL: Effect of Moderate vs Intensive Statin Therapy
|
|
PROVE-IT: Median LDL-C Levels During Study
|
|
PROVE-IT: Primary Composite End Point
|
|
ORION: Study Design
|
|
ORION: Effects of Rosuvastatin on Change in Carotid Plaque Volume, Composition
|
|
WOSCOPS: Effects of Lipid Lowering on Coronary Events in Primary Prevention Trial in Men
|
|
WOSCOPS: Relation of Baseline LDL-C to Event Rate
|
|
WOSCOPS: Relation of Baseline HDL-C to Event Rate
|
|
WOSCOPS: Relation Between Quintiles of LDL-C Reduction and CHD Events
|
|
Treating to New Targets: Mean Lipid Levels
|
|
TNT: Hazard Ratios for the Primary Outcome
|
|
TNT: Hazard Ratios for Primary Outcome Components
|
|
TNT: Hazard Ratios for Secondary Outcomes
|
|
Relationship Between LDL-C and Event Rates in TNT and Other Statin Trials
|
|
TNT: Safety Profile
|
|
SPARCL Primary Outcome: Fatal or Nonfatal Stroke
|
|
Swedish Register Study Design and Baseline Characteristics
|
|
Swedish Register Study: Early Statin Treatment Improves Post-AMI Survival Rates
|
|
Swedish Register Study: Implications for Early Statin Treatment
|
|
STELLAR: Percent Change in LDL-C From Baseline
|
|
STELLAR: Percent Change in HDL-C From Baseline
|
|
STELLAR: Percent of Patients at NCEP ATP III LDL-C Goal (6-Week Data)
|
SEACOAST: Combination Therapy for Increased Non–HDL-C
Primary Endpoint
|
|
Trends in Total Cholesterol for US Adults, 1960-1962 to 1999-2002
|
|
Lipid Lowering and Plaque Regression: Monotherapy Studies
|
|
Event Reduction in Angiographic Plaque Regression Trials
|
|
Effects of Lipid-Lowering Therapy on Endothelial Function in CHD Patients
|
|
Effect of Cholesterol Lowering on Myocardial Ischemia
|
|
TGs Predict CAD Risk Independently of TC and HDL-C
|
|
Association of Small, Dense LDL With Myocardial Infarction
|
|
ATP III: Special Populations—Women, Middle-Aged Men
|
|
Statin Advisory: Definitions of Muscle Toxicity
|
|
Statin Advisory: Monitoring Parameters, Follow-Up Schedule
|
|
Statin Advisory: Clinical Precautions When Prescribing Statin Therapy
|
|
Statin Advisory: Risk Factors for Statin-Associated Myopathy
|
|
Statin Advisory: Conclusions
|
|
ABCs of CVD Risk Management (cont.)
|
|
Treatment of Lipid Disorders in Patients With Diabetes
|
|
ATP III: Management of Very High LDL-C
|
|
Effects of Lipid Lowering on Endothelial Function: Hypercholesterolemic Patients
|
|
Effects of Lipid-Lowering Therapy on Myocardial Perfusion in CHD Patients
|
|
Metabolic Effects of Lipid-Lowering Agents on Lipoproteins
|
|
Colesevelam, Atorvastatin—Effects on Lipids
|
|
Common Drug Treatments for Patients With Metabolic Syndrome
|
|
Effect of Ezetimibe + Statin Therapy on Lipids in Patients with Primary Hypercholesterolemia
|
|
Effect of Ezetimibe + Atorvastatin on Lipids in Primary Hypercholesterolemia
|
|
Effect of Ezetimibe + Simvastatin on Lipids in Primary Hypercholesterolemia
|
|
Effect of Ezetimibe + Lovastatin on Lipids in Primary Hypercholesterolemia
|
|
Clinical Benefits of Cholesterol Reduction
|
|
Lipid Lowering and Plaque Regression: Combination Therapy Studies
|
|
Incidence of Myopathy in 3 UK Cohorts
|
|
Effect of Dual-Component E-R Niacin/Lovastatin on Lipids in Primary Hypercholesterolemia
|
|
Omega-3 Concentrate Plus Statin: Effects on TG
|
|
Summary of Effects of Lipid Lowering on Lipids and Clinical Events in Recent Statin Trials
|
|
Statins: Frequency of Proteinuria, Hematuria, and Proteinuria/Hematuria
|
|
LCL-C Lowering According to Statin and Dose: A Meta-Analysis of 164 Trials
|
|
Effect of Atorvastatin on Walking Distance in Patients With PAD
|
|
Reductions in Vascular Event Costs With a Statin
|
|
Effect of Statin Therapy on AMI Within 24 Hours of Hospitalization
|
|
Relative Risk for Major Vascular Events With Statin Therapy
|
|
PROVE-IT Substudy: Major Safety Outcomes
|
|
PROVE-IT Substudy: Primary Endpoint and Achieved LDL-C Levels
|
|
Switching Statins: Effects on Compliance and Persistence
|
|
Phenotypic Predictors of Response to Simvastatin
|
|
Effect of Cholesterol Lowering on Stroke Events: A Meta-analysis of Statin Trials
|
|
Effects of Statins on Stroke Events: A Meta-analysis of Primary- and Secondary-Prevention Trials
|
|
Impact of Lowering LDL-C on CVD Events and Total Mortality
|
|
Relation Between CHD Events and LDL-C Outcomes in Statin Trials
|
|
Atorvastatin: Percent of Patients With >1 Adverse Event (Pooled Analysis: Fixed-Dose Data Grouping)
|
|
Cholesterol Biosynthetic Pathway
|
|
Comparative Efficacy of Available Statins
|
|
Atorvastatin Dose-Response Relationship in Primary Hypercholesterolemia
|
|
Safety Summary for HMG-CoA Reductase Inhibitors
|
|
Risk of CHD Events and Level of Cholesterol
|
|
Effects of Three Treatments on CRP
|
|
Pathway Model and Therapies for Atherosclerosis, Risk for MI
|
|
Impact of Atorvastatin on Lipids in Patients With Hypertriglyceridemia
|
|
Effects of HRT and Simvastatin Compared in Hypercholesterolemic Postmenopausal Women
|
|
Rosuvastatin: Clinical Pharmacology
|
|
Association of Small, Dense LDL With Insulin Resistance
|
|
Statin Trials: Therapy Reduces Major Coronary Events in Women
|
|
Overall Risk Reduction for Major Coronary Events by Sex: A Meta-Analysis
|
|
Clinical Trial Findings: The Statins
|
|
Impact of Atorvastatin on Lipids in Postmenopausal Women
|
|
Impact of Statin-Induced Changes in LDL-C and HDL-C on Atheroma Burden (2 of 2)
|
|
P-OM3 Plus Simvastatin: Study Design
|
|
P-OM3 Plus Simvastatin: Changes in Lipids and Lipoprotein Particles From Baseline
|
|
Effect of Atorvastatin on Biomarkers in Patients With MetSyn: Study Design
|
|
Effect of Atorvastatin on hs-CRP in Patients with MetSyn
|
|
PROSPER: Association of Leptin With CVD
|
|
NHANES Extrapolation: Population Meeting JUPITER Study Eligibility
|
|
Population Estimatesa at ATP III Risk Categories with CRP ≥2 mg/L
|
|
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye: Substudy of ACCORD
|
|
ACCORD Eye: Progression of Diabetic Retinopathy By Treatment Group at Year 4
|
|
ACCORD Eye: Moderate Vision Loss By Treatment Group at Year 4
|
|
Benefit of Statins for Subjects With CVD but Without CV Risk Factors
|
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Results
|
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Additional Results at Year 1
|
|
Effect of Statins on Atherosclerosis After ACS: Design
|
|
Effect of Statins on Atherosclerosis After ACS: Percent Change in Atheroma Volume
|
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Design
|
|
ARBITER--6 HALTS: Effect of Niacin ER or Ezetimibe on CIMT
|
|
Results from ARBITER 6--HALTS: Effect of Niacin ER or Ezetimibe on CIMT
|
|
Statin Use and Risk for Diabetes: Design
|
|
Statin Use and Risk for Diabetes: Results
|
|
SEARCH: Design
|
|
SEARCH: Rate of Major Vascular Events
|
|
SEARCH: Additional Outcomes
|
|
Meta-analysis: Efficacy and Safety of Intensive LDL Lowering
|
|
Meta-analysis: Efficacy and Safety of Intensive LDL Lowering—Findings
|
|
ARBITER 6–Halts: Methods and Final Results
|
|
ARBITER 6–HALTS: Final Results
|
|
JUPITER Statin Use for Primary Prevention of CVD Events in Women
|
|
Meta-Analysis: Statin Use for Primary Prevention of CVD Events in Women
|
|
Statin Use and Risk for Diabetes: Design
|
Statin Use and Risk for Diabetes: Results
|
SEARCH: Design
|
SEARCH: Rate of Major Vascular Events
|
SEARCH: Additional Outcomes
|
Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD: Primary Endpoint
|
Meta-analysis: Efficacy and Safety of Intensive LDL Lowering
|
Meta-analysis: Efficacy and Safety of Intensive LDL Lowering—Findings
|
Pharmacologic Therapies: Other
|
|
Pharmacologic Therapies Other
|
|
|
|
|
|
CHARISMA: Clopidogrel + Aspirin vs Aspirin Alone in High-Risk CVD Patients
|
|
EPAT: Baseline Characteristics of Evaluable Patients
|
|
EPAT: Progression of Carotid Artery Intima-Media Thickness (IMT)
|
|
PERISCOPE: Study Design
|
|
PERISCOPE: Change in PAV
|
|
HERS: Combined HRT Does Not Decrease All-Cause Mortality
|
|
HERS: Primary CHD Events
|
|
HERS: HDL-C Distribution in a Cohort With CHD
|
|
HERS, HERS II: Relative Hazard of CHD Events
|
|
HERS: Risk of Cerebrovascular Disease Events
|
|
IBIS-2: Effects of Lp-PLA2 Inhibitor Darapladib on Coronary Atherosclerotic Plaque
|
|
IBIS-2: Decreases in Progression of Necrotic Core
|
|
JELIS: Study Design
|
|
JELIS: Multiple Risk Factorsa and Incidence of Major Coronary Events
|
|
JPAD: Study Design
|
|
JPAD Results: Primary Endpoint (CVD Composite)
|
|
JPAD Results: Primary Endpoint in Subgroups
|
|
JUPITER: Lipid and Hs-CRP Levels
|
|
JUPITER Results: Primary Endpoint
|
|
JUPITER Results: Components of Primary Endpoint
|
|
JUPITER Results: Summary
|
|
NHANES I Epidemiologic Follow-up Study: CHD Incidence and Survival in African American Men and Women
|
|
Impact of Estrogen and Progestin on Cholesterol Concentrations
|
|
HRT Effects on C-Reactive Protein Levels: PEPI Trial Subgroup
|
|
MORE: Cardiovascular Events at 4-Year Follow-up
|
|
WHI trial of Estrogen, Progestin Ended
|
|
WHI: CHD, Stroke Outcomes in Estrogen-Alone Arm
|
|
Swedish Register Study Design and Baseline Characteristics
|
|
Treatment Options for Peripheral Arterial Disease
|
|
Treatment Options for Peripheral Arterial Disease (cont)
|
|
Event Reduction in Angiographic Plaque Regression Trials
|
|
Angiographically Inapparent Atheroma
|
|
ATP III: LDL-C Measurements in Patients Hospitalized for Major Coronary Events
|
|
Statin Advisory: Risk Factors for Statin-Associated Myopathy
|
|
Effects of Drug Therapy and Diet on Lipids
|
|
ABCs of CVD Risk Management
|
|
Common Drug Treatments for Patients With Metabolic Syndrome
|
|
Effects of Three Treatments on CRP
|
|
Lowest Effective Aspirin Dose for MI and Stroke Reduction
|
|
Early Primary-Prevention Trials: Overview
|
|
Early Secondary-Prevention Trials: Overview
|
|
Pathway Model and Therapies for Atherosclerosis, Risk for MI
|
|
Effect of Rimonabant on Cardiometabolic Risk Factors
|
|
Impact of Atorvastatin on Lipids in Patients With Hypertriglyceridemia
|
|
Effects of HRT and Simvastatin Compared in Hypercholesterolemic Postmenopausal Women
|
|
HRT Effects on C-Reactive Protein Levels
|
|
Raloxifene: Effects on Lipids in Postmenopausal Women
|
|
Rosuvastatin: Clinical Pharmacology
|
|
PROactive 10 Substudy: Time to First Event from MACE Endpointa
|
|
PROactive 10 Substudy: Time to All-Cause Mortality, Nonfatal MIa, Nonfatal Stroke, or ACS
|
|
PROSPER: Association of Leptin With Diabetes
|
|
ADA/AHA/ACC: Recommendations for Use of Aspirin for Primary Prevention of CV Events in People With Diabetes
|
|
Reduction in Vascular Events With Aspirin Treatment: Primary Prevention Trials
|
|
Reduction in Vascular Events With Aspirin Treatment: Secondary Prevention Trials
|
|
SU.FOL.OM-3: Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD—Design
|
|
Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD: Primary Endpoint
|
|
Systematic Review of CV Risk With NSAID Use: Design
|
|
Review of CV Risk with NSAID Use: Results
|
|
ADA/AHA/ACC: Recommendations for Use of Aspirin for Primary Prevention of CV Events in People With Diabetes
|
SU.FOL.OM-3: Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD—Design
|
Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD: Primary Endpoint
|
Systematic Review of CV Risk With NSAID Use: Design
|
Review of CV Risk with NSAID Use: Results
|
Special Populations
|
|
Patients With Diabetes
|
|
|
|
|
|
ADA Criteria for the Diagnosis of Diabetes
|
|
ADA Criteria for Testing for Diabetes in Asymptomatic Adults
|
|
ADA Guidelines for Foot Care in Patients With Diabetes
|
|
ADA Guidelines for Foot Care in Patients With Diabetes (cont)
|
|
ADA Guidelines for Retinopathy Management in Diabetes
|
|
ADA Guidelines for Type 2 Diabetes in Children and Adolescents: Screening and Treatment
|
|
ADA Guidelines for Treatment of Older Adults With Diabetes
|
|
ADA Nutrition Strategies for Weight Loss
|
|
ADA Recommendations for Medical Nutrition Therapy
|
|
ADA Recommendations for Primary Prevention of Diabetes With Medical Nutrition Therapy
|
|
ADA Recommendations for Aspirin Therapy in Diabetes
|
|
ADA Recommendations for Diabetes Care in the Hospital
|
|
ADA Recommendations for Diabetes Care in the Hospital (cont)
|
|
ADA Recommendations for Smoking Cessation in Diabetes
|
|
ADA Treatment Recommendations for Nephropathy
|
|
ADA: Goals for Glycemic, Blood Pressure, and Lipid Control
|
|
ADA: Physical Activity/Exercise Recommendations for Patients With Diabetes
|
|
ADA Recommendations on Bariatric Surgery in Patients With Diabetes
|
|
ADA Recommendations for Immunization in Patients With Diabetes
|
|
ADA Guidelines: Correlation of A1C With Average Glucose
|
|
ADA Recommendations for Neuropathy Screening and Treatment
|
|
ADA: Categories of Increased Risk for Diabetes (Prediabetes)
|
|
ADA Recommendations for Detection and Diagnosis of Gestational Diabetes Mellitus
|
|
ADA Guidelines: Common Comorbidities Associated With Diabetes
|
|
ADA Guidelines: A1C Recommendations
|
|
ADA Guidelines: Glycemic Recommendations for Nonpregnant Adults With Diabetes
|
|
ADA Guidelines: Recommendations for Type 2 Diabetes Therapy
|
|
ADA Guidelines: Recommendations for Hypoglycemia
|
|
ADA Guidelines: Recommendations for Prevention/Delay of Type 2 Diabetes
|
|
ADA Guidelines: Recommendations for Diabetes Self-Management Education (DSME)
|
|
ADA Guidelines: Noninsulin Therapies for Hyperglycemia in Type 2 Diabetes (1 of 2)
|
|
ADA Guidelines: Noninsulin Therapies for Hyperglycemia in Type 2 Diabetes (2 of 2)
|
|
Look AHEAD: Design
|
|
Look AHEAD: Interventions
|
|
Look AHEAD: Change in Body Weight Across BMI Groups
|
|
Look AHEAD: Change in Fitness Levels Across BMI Groups
|
|
Look AHEAD: Additional Results
|
|
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Design
|
|
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Results
|
|
Effects of Liraglutide and Insulin on Cardiovascular Disease Risk Factors
|
|
Liraglutide Effect on Cardiovascular Disease: Results Among Patients Switched from Exenatide
|
|
San Luigi Gonzaga Diabetes Study: Design
|
|
San Luigi Gonzaga Diabetes Study: Results
|
|
AFCAPS/TexCAPS: Primary End Point Event Rates Within Demographic and Risk Factor Subgroups
|
|
Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes
|
|
Finnish Diabetes Prevention Study: Success in Achieving Treatment Goals at 1 Year
|
|
Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes
|
|
Diabetes Prevention Program: Study Design
|
|
Diabetes Prevention Program
|
|
ASCOT-LLA: Primary End Point in Subgroups
|
|
FIELD: Fenofibrate Effect on Lipids
|
|
DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes
|
|
DAIS: Mean Baseline Lipoprotein Levels
|
|
DAIS: Interim Lipid Results in Patients With Type 2 Diabetes
|
|
DAIS: Final Results in Patients With Types 2 Diabetes
|
|
Framingham Heart Study 30-Year Follow-Up: CVD Events in Patients With Diabetes (Ages 35-64)
|
|
Abnormal Lipid Levels in Men With Type 2 Diabetes
|
|
Abnormal Lipid Levels in Women With Type 2 Diabetes
|
|
Secondary Prevention: CHD Risk Reduction in the 4S Subgroup of Patients WIth Diabetes
|
|
4S: Total Mortality Reduction in a Subgroup of Patients With Diabetes
|
|
4S: Major CHD Event Reduction in a Subgroup of Patients With Diabetes
|
|
4S: Treatment Benefit in Subgroup With Impaired Fasting Glucose (FG 110-125 mg/dL)
|
|
CARE: Major Coronary Events in the Diabetic Subgroup
|
|
ARIC: CHD Events, CVD Mortality With/Without MI or Diabetes
|
|
Collaborative Atorvastatin Diabetes Study (CARDS): Results Summary
|
|
Collaborative Atorvastatin Diabetes Study (CARDS): Major CVD Events
|
|
CARDS: Effect of Treatment on Primary and Secondary End Points
|
|
CARDS: Effect of Treatment on Primary End Point by Lipid Level
|
|
ACCORD: Study Design
|
|
ACCORD: A1c Levels, Hypoglycemia, and Weight Gain
|
|
ACCORD: Death from Any Cause
|
|
ACCORD: Results
|
|
ADVANCE: Study Design
|
|
ADVANCE: A1c Levels, Hypoglycemia, and End-Study Weight
|
|
ADVANCE: Primary Endpoints
|
|
ADVANCE: Death from Any Cause
|
|
DIACOR Substudy: Effects of Simvastatin and/or Fenofibrate on Lipoprotein Subparticles
|
|
DIACOR Substudy: Level of LDL Pattern B at Baseline and Week 12
|
|
PERISCOPE: Study Design
|
|
PERISCOPE: Change in PAV
|
|
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
|
|
ACCORD BP: Effects of Intensive BP_Control on Type 2 Diabetes
|
|
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Diabetic Status
|
|
Primary CHD Prevention in Patients With Type 2 Diabetes: The Helsinki Heart Study
|
|
HPS Substudy: First Major Vascular Event and Patients With Diabetes
|
|
HPS Substudy: First Major Coronary Event and Stroke by Prior to Diabetes Status
|
|
HPS Substudy: First Major Vascular Event by LDL-C and Prior Diabetes Status
|
|
HPS Diabetes Substudy: Absolute Effects on 5-Year Rates of First Major Vascular Event
|
|
JPAD Results: Primary Endpoint in Subgroups
|
|
JUPITER: Lipid and Hs-CRP Levels
|
|
JUPITER Results: Primary Endpoint
|
|
JUPITER Results: Components of Primary Endpoint
|
|
JUPITER Results: Summary
|
|
CHD Mortality and Hyperinsulinemia: Paris Prospective Study (N=943)
|
|
Relation Between Baseline Fasting Insulin and Ischemic Heart Disease
|
|
NHANES III: Age-Adjusted Prevalence of Individual Risk Factors for the Metabolic Syndrome
|
|
NHANES III: Age-Adjusted Prevalence of >3 Risk Factors for the Metabolic Syndrome
|
|
NHANES III: Age-Specific Prevalence of the Metabolic Syndrome
|
|
Post-CABG: Effect of Aggressive Lipid Lowering on a Subgroup of Patients With Diabetes
|
|
PREDICT: Study Design
|
|
PREDICT: Primary Endpoint Event Rates in Successive Categories of CAC Score
|
|
Prevalence of Macrovascular Disease and CHD According to Quintiles of Fasting C-Peptide
|
|
The Strong Heart Study: Differences in CVD Risk Factors by Diabetic Status in Men and Women
|
|
Strong Heart Study: Non–HDL-C as CVD Risk Predictor in Patients With Diabetes
|
|
Strong Heart Study: Non–HDL-C Compared With Other CVD Risk Predictors
|
|
Trends in CHD Risk Among Adults With Diabetes: Design
|
|
Trends in CHD Risk Among Adults With Diabetes: Results
|
|
Hypertriglyceridemia and CHD Risk: Associated Abnormalities
|
|
Interrelation Between Atherosclerosis and Insulin Resistance
|
|
Progression to Atherosclerotic Clinical Events in Patients With Diabetes
|
|
Atherosclerosis in Diabetes
|
|
Insulin Resistance and Atherosclerosis: Posited Relationships
|
|
ATP III: The Metabolic Syndrome
|
|
ATP III: Management of Diabetic Dyslipidemia
|
|
Updated Criteria for Clinical Diagnosis of Metabolic Syndrome
|
|
ADA: Glycemic Control, BP, and Lipid Targets in Type 2 Diabetes
|
|
ADA: Treatment Decisions by LDL-C Levels in Adults With Type 2 Diabetes
|
|
ABCs of CVD Risk Management (cont.)
|
|
TG Metabolism in CHD: Studies in the Postprandial State
|
|
Treatment of Lipid Disorders in Patients With Diabetes
|
|
Hypertriglyceridemia and Risk for CHD
|
|
Association of Small, Dense LDL With Insulin Resistance
|
|
Frequent Causes of Secondary Hypertriglyceridemia
|
|
Association of MI With the Metabolic Syndrome and Individual Components
|
|
Association of Stroke With the Metabolic Syndrome and Individual Components
|
|
Metabolic Syndrome and Mortality From CVD, CHD
|
|
Metabolic Syndrome and 10-Year CVD Risk
|
|
Mortality Rates for Ischemic Heart Disease in Patients With and Without Diabetes
|
|
Women, Diabetes, and CHD
|
|
Potential Mechanisms of Atherogenesis in Diabetes
|
|
Clinical Trial Findings: The Statins
|
|
Effect of Atorvastatin on Biomarkers in Patients With MetSyn: Study Design
|
|
Effect of Atorvastatin on hs-CRP in Patients with MetSyn
|
|
PROactive 10 Substudy: Time to First Event from MACE Endpointa
|
|
PROactive 10 Substudy: Time to CV Death, Nonfatal MIa, Nonfatal Stroke
|
|
PROSPER: Association of Leptin With Diabetes
|
|
PROSPER: Association of Leptin With CVD
|
|
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye: Substudy of ACCORD
|
|
ACCORD Eye: Progression of Diabetic Retinopathy By Treatment Group at Year 4
|
|
ACCORD Eye: Moderate Vision Loss By Treatment Group at Year 4
|
|
Liraglutide Vs Sigagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: Design
|
|
Liraglutide Vs Sigagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: A1C Reduction
|
|
CANOE: Low-Dose Combination Therapy With Rosiglitazone Plus Metformin for Diabetes Prevention
|
|
CANOE: Development of New-Onset Diabetes With Low-Dose Combination Therapy Vs Placebo
|
|
LOADD: Primary Endpoint—Difference in A1C at 6 Months
|
|
ADA/AHA/ACC: Recommendations for Use of Aspirin for Primary Prevention of CV Events in People With Diabetes
|
|
Impact of Higher Heart Rate on Development of Cardiometabolic Risk Factors After 20 Years
|
|
RECORD: Bone Fracture Rates in Upper and Distal Lower Limbs
|
|
RECORD: Conclusion
|
|
CVD Mortality Risk Rate Among Men With MetSyn and Diabetes, Alone and in Combination
|
|
Hazard Ratios of CVD Mortality Among Men with MetSyn and Diabetes, Alone and in Combination
|
|
ADA Nutrition Strategies, Interventions for Improved Metabolic Control
|
|
AHA Heart Disease and Stroke Statistics: Diabetes Prevalence
|
|
AHA Heart Disease and Stroke Statistics: Diabetes Mortality
|
|
Association Between New-Onset Diabetes and Antihypertensive Therapy
|
|
Patients With Hypertension
|
|
|
|
|
|
AFCAPS/TexCAPS: Primary End Point Event Rates Within Demographic and Risk Factor Subgroups
|
|
ALLHAT-LLT: All-Cause Mortality
|
|
ALLHAT-LLT: Comparison to Other Large, Long-Term Statin Trials
|
|
ASCOT–LLA: Study Design
|
|
ASCOT-LLA: Primary End Point
|
|
ASCOT-LLA: Primary End Point in Subgroups
|
|
ASCOT-LLA: Effect of Atorvastatin vs Placebo on CV and Coronary End Points
|
|
CARE: Reduction of Coronary Events in Patients With Diabetes
|
|
ACCORD BP: Effects of Intensive BP_Control on Type 2 Diabetes
|
|
JNC 7: Classification and Management of Blood Pressure for Adults
|
|
TROPHY: Analysis of New-Onset Hypertension
|
|
UKPDS: Tight Blood Pressure Control vs Less Tight Control in Patients With Type 2 Diabetes
|
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Design
|
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Results
|
|
Treatment Options for Peripheral Arterial Disease
|
|
Treatment Options for Peripheral Arterial Disease (cont)
|
|
JNC 7: Treatment Algorithm for Hypertension
|
|
HF Rates in Hypersensitive Blacks and Non-Blacks: ALLHAT
|
|
Safety and Tolerability of Monotherapy, Combination BP Therapy
|
|
ASCOT-LLA: Incidence for Total CVD Events/Procedures in Patients With Diabetes
|
|
Effect of Monotherapy, Combination Therapy on Blood Pressures
|
|
Adjusted Hazard Ratios for First Cardiovascular Event based on CRP, BP
|
|
Renin-Angiotensin Blockade: Beyond BP Lowering
|
|
Lifestyle Modification: Effect on CVD Risk Factors (DPP)
|
|
CVD Event-Free Survival Based on CRP, BP Levels
|
|
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye: Substudy of ACCORD
|
|
ACCORD Eye: Progression of Diabetic Retinopathy By Treatment Group at Year 4
|
|
ACCORD Eye: Moderate Vision Loss By Treatment Group at Year 4
|
|
Impact of Higher Heart Rate on Development of Cardiometabolic Risk Factors After 20 Years
|
|
Urinary Sodium Excretion and Health Outcomes: Design
|
|
Urinary Sodium Excretion and Health Outcomes: CV Results
|
|
Urinary Sodium Excretion and Health Outcomes: Hypertension, BP Results
|
|
Effect of Dietary and Lifestyle Factors on Hypertension Among Women: Design
|
|
Association Between New-Onset Diabetes and Antihypertensive Therapy
|
|
Effect of Dietary and Lifestyle Factors on Hypertension Among Women: Results
|
|
Women
|
|
|
|
|
|
AFCAPS/TexCAPS: Effects of LDL C Lowering in Patients With Average Cholesterol Levels
|
|
4S: Effect of LDL-C Lowering on Coronary Events in Secondary Prevention Trial in Men and Women
|
|
4S: Lipid Lowering Reduces CHD Event Rates in >65-Year Old Subjects
|
|
EPAT: Baseline Characteristics of Evaluable Patients
|
|
EPAT: Progression of Carotid Artery Intima-Media Thickness (IMT)
|
|
Abnormal Lipid Levels in Women With Type 2 Diabetes
|
|
LRC Follow-up Study: CVD Mortality by Non-HDL-C and LDL-C in Women
|
|
LIPID: Effect of Lipid Lowering on Lipid Values and Coronary Events in CHD Patients With Average Cholesterol
|
|
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Sex
|
|
HERS: Combined HRT Does Not Decrease All-Cause Mortality
|
|
HERS: Primary CHD Events
|
|
HERS: HDL-C Distribution in a Cohort With CHD
|
|
HERS, HERS II: Relative Hazard of CHD Events
|
|
HERS: Risk of Cerebrovascular Disease Events
|
|
NHANES I Epidemiologic Follow-up Study: CHD Incidence and Survival in African American Men and Women
|
|
Prevalence of Overweight in US Women: NHANES 1999-2000
|
|
Prevalence of Obesity in US Women: NHANES 1999-2000
|
|
Post-CABG: Aggressive LDL-C Lowering Delays Progression of Atherosclerosis in Women, Elderly, and Patients With Selected CHD Risk Factors
|
|
NHANES III: Age-Specific Prevalence of the Metabolic Syndrome
|
|
Impact of Estrogen and Progestin on Cholesterol Concentrations
|
|
HRT Effects on C-Reactive Protein Levels: PEPI Trial Subgroup
|
|
MORE: Cardiovascular Events at 4-Year Follow-up
|
|
SHEEP: Risk Factors for Nonfatal MI in Men and Women
|
|
WISE: Prevalence of Angiographic CAD Based on BMI, Metabolic Status
|
|
WHI trial of Estrogen, Progestin Ended
|
|
Outcomes in WHI Trial of Estrogen, Progestin
|
|
WHI: CHD, Stroke Outcomes in Estrogen-Alone Arm
|
|
The Strong Heart Study: Differences in CVD Risk Factors by Diabetic Status in Men and Women
|
|
WISE Study: Review of Ischemic Heart Disease in Women
|
|
Characteristics of LDL Phenotype B
|
|
ATP III: Features Shared With ATP II
|
|
ATP III: Special Populations—Women, Middle-Aged Men
|
|
ATP III Framingham Risk Scoring–Assessing CHD Risk in Women
|
|
ATP III Framingham Risk Scoring–Step 7: CHD Risk for Women
|
|
AHA Evidence-Based Guidelines for CVD Prevention in Women
|
|
Statin Advisory: Risk Factors for Statin-Associated Myopathy
|
|
Effects of Three Treatments on CRP
|
|
Effects of HRT and Simvastatin Compared in Hypercholesterolemic Postmenopausal Women
|
|
HRT Effects on C-Reactive Protein Levels
|
|
Raloxifene: Effects on Lipids in Postmenopausal Women
|
|
Women, Diabetes, and CHD
|
|
Adjusted Hazard Ratios for First Cardiovascular Event based on CRP, BP
|
|
Leading Causes of Death for US Females, 2001
|
|
CVD Mortality Trends for US Males and Females
|
|
ATP III: Special Populations—Older Adults, Younger Adults
|
|
ATP III vs ATP II: Increases in Treatment-Eligible Primary-Prevention Patients
|
|
Adjusted Relative Risk for First Cardiovascular Event Based on CRP, LDL-C
|
|
Event-Free Survival With CRP, LDL-C Levels Above or Below the Median
|
|
CVD Event-Free Survival Based on CRP, BP Levels
|
|
Awareness and Preventive Action for Cardiovascular Health in Women
|
|
Statin Trials: Therapy Reduces Major Coronary Events in Women
|
|
Overall Risk Reduction for Major Coronary Events by Sex: A Meta-Analysis
|
|
Clinical Trial Findings: The Statins
|
|
Impact of Atorvastatin on Lipids in Postmenopausal Women
|
|
CHD in the United States
|
|
Women’s Health Study: Design
|
|
Women’s Health Study: Association of Fasting and Nonfasting Lipids With CVD
|
|
Defining Normal Distributions of CAC Framingham Cohorts
|
|
Excess Weight and CHD Risk Among Men Vs Women
|
|
Effect of Dietary and Lifestyle Factors on Hypertension Among Women: Design
|
|
Effect of Dietary and Lifestyle Factors on Hypertension Among Women: Results
|
|
JUPITER Statin Use for Primary Prevention of CVD Events in Women
|
|
Meta-Analysis: Statin Use for Primary Prevention of CVD Events in Women
|
|
Younger/Older Patients
|
|
|
|
|
|
4S: Lipid Lowering Reduces CHD Event Rates in >65-Year Old Subjects
|
|
4S: Impact of Drug Therapy on Lipids and Lipoproteins in Older Adults With Hypercholesterolemia
|
|
4S: Reduction in Coronary Events and Revascularizations in Older Adults With Established CHD
|
|
4S: Survival of Major Coronary Events in Older Adults
|
|
CARE: Impact of Drug Therapy on Lipids and Lipoproteins in Older Patients With MI
|
|
CARE: Reduction in Coronary Events, Revascularizations, and Stroke in Older Adults With MI and Average Cholesterol Levels
|
|
CARE: Incidence of Coronary Events in Younger Versus Older Patients
|
|
ASCOT-LLA: Primary End Point in Subgroups
|
|
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Sex
|
|
LIPID: Reduction in nonfatal MI and CHD Death Risk Stratified by Prerandomization Age
|
|
PDAY: Percentage of Right Coronary Artery Intimal Surface Affected With Early Atherosclerosis
|
|
PDAY: Prevalence of lesions in LAD
|
|
PDAY: Prevalence of Risk Factors
|
|
PDAY: Prevalence of Lesions by Smoking and Non-HDL-C Status
|
|
Age-Adjusted Total Cholesterol Levels in NHANES III vs NHANES 1999-2000
|
|
Post-CABG: Aggressive LDL-C Lowering Delays Progression of Atherosclerosis in Women, Elderly, and Patients With Selected CHD Risk Factors
|
|
PROSPER: Primary Composite End Point Results CHD Death, Nonfatal MI, Fatal or Nonfatal Stroke
|
|
NHANES III: Age-Specific Prevalence of the Metabolic Syndrome
|
|
WESDR: Hyperglycemia and the Risk for Vascular Complications in Older-Onset Diabetes
|
|
WESDR: Hyperglycemia and the Risk for Cause-Specific CVD Mortality
|
|
Composite CIMT With Metabolic Syndrome in Young Adults
|
|
ATP III: Features Shared With ATP II
|
|
ATP III: Special Populations—Women, Middle-Aged Men
|
|
Eligible Primary-Prevention Patients by Age and Treatment Scenario (ATP III vs ATP II)
|
|
Statin Advisory: Risk Factors for Statin-Associated Myopathy
|
|
ATP III vs ATP II: Increases in Treatment-Eligible Primary-Prevention Patients
|
|
Overall Risk Reduction for Major Coronary Events by Sex: A Meta-Analysis
|
|
Clinical Trial Findings: The Statins
|
|
CHD in the United States
|
|
Elevated TC Effects on Risk of CHD Death in Younger Men: A Meta-Analysis
|
|
PROSPER: Association of Leptin With Diabetes
|
|
PROSPER: Association of Leptin With CVD
|
|
NHANES Extrapolation: Population Meeting JUPITER Study Eligibility
|
|
Population Estimatesa at ATP III Risk Categories with CRP ≥2 mg/L
|
|
PROSPER: Association of Leptin With CVD
|
|
PROSPER: Association of Leptin With Diabetes
|
|
Multiethnic Patients
|
|
|
|
|
|
NOMAS: Study Design
|
|
NOMAS: Event-Free Curves Based on MetSyn and Endothelial Dysfunction
|
|
SANDS: Study Design
|
|
SANDS: Change in CIMT with Aggressive vs Standard Therapy
|
|
MESA: Study Design
|
|
MESA: CVD and CHD Risk by CIMT or CAC Score
|
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Design
|
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Results
|
|
Trends in CHD Risk Among Adults With Diabetes: Design
|
|
Trends in CHD Risk Among Adults With Diabetes: Results
|
|
ADA Criteria for Testing for Diabetes in Asymptomatic Adults
|
ADA Guidelines for Foot Care in Patients With Diabetes
|
ADA Guidelines for Foot Care in Patients With Diabetes (cont)
|
ADA Guidelines for Retinopathy Management in Diabetes
|
ADA Guidelines for Type 2 Diabetes in Children and Adolescents: Screening and Treatment
|
ADA Guidelines for Treatment of Older Adults With Diabetes
|
ADA Nutrition Strategies for Weight Loss
|
ADA Recommendations for Medical Nutrition Therapy
|
ADA Recommendations for Primary Prevention of Diabetes With Medical Nutrition Therapy
|
ADA Recommendations for Aspirin Therapy in Diabetes
|
ADA Recommendations for Diabetes Care in the Hospital
|
ADA Recommendations for Diabetes Care in the Hospital (cont)
|
ADA Recommendations for Smoking Cessation in Diabetes
|
ADA Treatment Recommendations for Nephropathy
|
ADA: Goals for Glycemic, Blood Pressure, and Lipid Control
|
ADA: Physical Activity/Exercise Recommendations for Patients With Diabetes
|
ADA Recommendations on Bariatric Surgery in Patients With Diabetes
|
ADA Recommendations for Immunization in Patients With Diabetes
|
ADA Guidelines: Correlation of A1C With Average Glucose
|
ADA Recommendations for Neuropathy Screening and Treatment
|
ADA: Categories of Increased Risk for Diabetes (Prediabetes)
|
ADA Recommendations for Detection and Diagnosis of Gestational Diabetes Mellitus
|
ADA Guidelines: Common Comorbidities Associated With Diabetes
|
ADA Guidelines: A1C Recommendations
|
ADA Guidelines: Glycemic Recommendations for Nonpregnant Adults With Diabetes
|
ADA Guidelines: Recommendations for Type 2 Diabetes Therapy
|
ADA Guidelines: Recommendations for Hypoglycemia
|
ADA Guidelines: Recommendations for Prevention/Delay of Type 2 Diabetes
|
ADA Guidelines: Recommendations for Diabetes Self-Management Education (DSME)
|
ADA Guidelines: Noninsulin Therapies for Hyperglycemia in Type 2 Diabetes (1 of 2)
|
ADA Guidelines: Noninsulin Therapies for Hyperglycemia in Type 2 Diabetes (2 of 2)
|
Look AHEAD: Design
|
Look AHEAD: Interventions
|
Look AHEAD: Change in Body Weight Across BMI Groups
|
Look AHEAD: Change in Fitness Levels Across BMI Groups
|
Look AHEAD: Additional Results
|
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Design
|
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Results
|
Effects of Liraglutide and Insulin on Cardiovascular Disease Risk Factors
|
Liraglutide Effect on Cardiovascular Disease: Results Among Patients Switched from Exenatide
|
San Luigi Gonzaga Diabetes Study: Design
|
San Luigi Gonzaga Diabetes Study: Results
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Design
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Results
|
Trends in CHD Risk Among Adults With Diabetes: Design
|
Trends in CHD Risk Among Adults With Diabetes: Results
|
Urinary Sodium Excretion and Health Outcomes: Design
|
Urinary Sodium Excretion and Health Outcomes: CV Results
|
Urinary Sodium Excretion and Health Outcomes: Hypertension, BP Results
|
Atherogenic Dyslipidemia
|
|
Didactic
|
|
|
|
|
|
Residual Cardiovascular Risk in Major Statin Trials
|
|
TGs and CHD Risk: Meta-Analysis of 29 Studies in Western Populations
|
|
Association of TG Levels and Incident CVD According to Fasting Status
|
|
Risk for MI, IHD, and Total Death by Nonfasting TG Increases
|
|
TG Level Remains A CVD Risk Factor Among Statin-Treated Patients
|
|
Non–HDL-C and CVD Risk
|
|
CHD Risk: HDL-C Versus LDL-C as Predictor
|
|
Statin Therapy Does Not Eliminate CVD Risk Associated With Low HDL-C
|
|
Underestimation of Number of LDL Particles With Increased Small LDL
|
|
TRIMS: Increased LDL Particle Size With Fenofibrate in HyperTG Patients Is Associated With End-of-Treatment TG
|
|
Look AHEAD: Improvement in Metabolic Syndrome Components at 1 Year
|
|
Pharmacologic Options for Managing Atherogenic Dyslipidemia
|
|
Coronary Drug Project: Niacin Effects on CVD, Mortality
|
|
HHS: Primary Prevention With Gemfibrozil
|
|
VA-HIT: Effect of Gemfibrozil on Primary Endpoint, Lipids
|
|
VA-HIT: LDL, HDL Particle Numbers Are Significant, Independent Predictors of New CHD Events
|
|
MI Prevention With Bezafibrate in Metabolic Syndrome
|
|
FIELD: End of Study Lipid Results
|
|
FIELD: Primary and Secondary Endpoints
|
|
Omega-3 Acid Ethyl Esters: Secondary-Prevention Studies
|
|
GISSI-Prevenzione: Time Course of Clinical Events
|
|
Omega-3 Acid Ethyl Esters: Lipid Effects in Patients with TG>500 mg/dL
|
|
Pharmacologic Options for Managing Atherogenic Dyslipidemia
|
|
SAFARI: Combination Therapy in Patients With Combined Hyperlipidemia
|
|
SAFARI: Effects on LDL Particle Subclasses
|
|
Atorvastatin and Fenofibrate Alone or in Combination in Patients With Type 2 Diabetes
|
|
Statin-Fibrate Combination Therapy: Pharmacokinetic Interactions
|
|
Lovastatin ± Niacin: Lipid Effects
|
|
HATS: Angiographic and Clinical Endpoints After 3 Years
|
|
ARBITER 2: Statin-Placebo Versus Statin-Niacin (1 of 2)
|
|
ARBITER 2: Statin-Placebo Versus Statin-Niacin (2 of 2)
|
|
Omega-3 Acid Ethyl Esters in Combination With Atorvastatin
|
|
Omega-3 Acid Ethyl Esters and Simvastatin in Patients With Combined Hyperlipidemia
|
|
COMBOS: Omega-3 Acid Ethyl Esters and Simvastatin in Patients with High TGs
|
|
JELIS: Incidence of Coronary Events
|
|
ATP III: Management of Elevated TG
|
|
Conclusions
|
|
Case Study
|
|
|
|
|
|
Patient Presentation
|
|
Initial Lab Values
|
|
What the Evidence Says
|
|
Treatment Recommendation
|
|
3-Month Follow-Up
|
|
Treatment Considerations
|
|
2-Month Follow-up
|
|
What the Evidence Says
|
|
What the Evidence Says (cont’d)
|
|
Treatment Recommendation
|
|
What the Evidence Says
|
|
Treatment Recommendation
|
|
What the Evidence Says
|
|
AHA Scientific Statement on Omega-3 Acid Ethyl Esters Intake
|
|
Conclusion
|
|
Risk Assessment
|
|
Risk Assessment
|
|
|
|
|
|
San Luigi Gonzaga Diabetes Study: Design
|
|
San Luigi Gonzaga Diabetes Study: Results
|
|
SANDS: Study Design
|
|
SANDS: Change in CIMT with Aggressive vs Standard Therapy
|
|
MESA: Study Design
|
|
MESA: CVD and CHD Risk by CIMT or CAC Score
|
|
JELIS: Effects of EPA on Major Coronary Events in Subjects With High TG/Low HDL-C
|
|
PREDICT: Study Design
|
|
PREDICT: Primary Endpoint Event Rates in Successive Categories of CAC Score
|
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Design
|
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Results
|
|
Trends in CHD Risk Among Adults With Diabetes: Design
|
|
Trends in CHD Risk Among Adults With Diabetes: Results
|
|
Prediction of CV Events and Mortality Using ABI and FRS
|
|
Effect of Inclusion of ABI on 10-Year Cardiovascular Mortality
|
|
Association of Subclinical Atherosclerosis With FRS
|
|
Relation of Subclinical Atherosclerosis With Family History of Premature CAD
|
|
Average Carotid Wall Thicknessa in First-Degree Relatives Vs Controlsb
|
|
Overview: Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)
|
|
Consensus Recommendations for Lp-PLA2 Testing
|
|
Women’s Health Study: Design
|
|
Defining Normal Distributions of CAC Framingham Cohorts
|
|
Defining Normal Distributions of CAC: Participant Characteristics
|
|
CVD Event Prediction Among Subjects With Subclinical Atherosclerosis and Low HDL-C
|
|
CVD Event Prediction Among Subjects With Subclinical Atherosclerosis and Low HDL-C: 5-Year Follow-Up
|
|
Relationship of Elevated LDL-C and Systolic BP With CAC
|
|
Prevalence of CAC Based on LDL-C Tertilesa Across SBP Levels
|
|
Use of CRP to Assess CVD Risk Across Age Groups: Study Design
|
|
Use of CRP to Assess CVD Risk Across Age Groups: Results
|
|
Excess Weight and CHD Risk Among Men Vs Women
|
|
Prediction of CV Events Using Various Biomarkersa
|
|
Impact of Hyperglycemia on CVD Risk: Design
|
|
Impact of Hyperglycemia on CVD Risk: Results–Relative Risk of CVD
|
|
Impact of Hyperglycemia on CVD Risk: Results–Risk of CVD by A1C
|
|
Impact of Hyperglycemia on CVD Risk: Results–Absolute Risk of CVD
|
|
Metabolic Syndrome and CV Risk: Meta-Analysis
|
|
SEARCH: Design
|
|
SEARCH: Rate of Major Vascular Events
|
|
SEARCH: Additional Outcomes
|
|
Impact of Diet and Physical Activity on Weight Loss, Cardiometabolic Risk Factors: Results
|
|
SU.FOL.OM-3: Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD—Design
|
|
Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD: Primary Endpoint
|
|
Meta-analysis: Efficacy and Safety of Intensive LDL Lowering
|
|
Meta-analysis: Efficacy and Safety of Intensive LDL Lowering—Findings
|
|
Urinary Sodium Excretion and Health Outcomes: Design
|
|
Urinary Sodium Excretion and Health Outcomes: CV Results
|
|
Urinary Sodium Excretion and Health Outcomes: Hypertension, BP Results
|
|
Systematic Review of CV Risk With NSAID Use: Design
|
|
Review of CV Risk with NSAID Use: Results
|
|
San Luigi Gonzaga Diabetes Study: Design
|
San Luigi Gonzaga Diabetes Study: Results
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Design
|
BP and Type 2 Diabetes Risk in African Americans and Whites: Results
|
Trends in CHD Risk Among Adults With Diabetes: Design
|
Trends in CHD Risk Among Adults With Diabetes: Results
|
Impact of Hyperglycemia on CVD Risk: Design
|
Impact of Hyperglycemia on CVD Risk: Results–Relative Risk of CVD
|
Impact of Hyperglycemia on CVD Risk: Results–Risk of CVD by A1C
|
Impact of Hyperglycemia on CVD Risk: Results–Absolute Risk of CVD
|
Metabolic Syndrome and CV Risk: Meta-Analysis
|
SEARCH: Design
|
SEARCH: Rate of Major Vascular Events
|
SEARCH: Additional Outcomes
|
Impact of Diet and Physical Activity on Weight Loss, Cardiometabolic Risk Factors: Results
|
SU.FOL.OM-3: Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD—Design
|
Effects of B Vitamins and Omega-3 Acid Ethyl Esters on CVD: Primary Endpoint
|
Meta-analysis: Efficacy and Safety of Intensive LDL Lowering
|
Meta-analysis: Efficacy and Safety of Intensive LDL Lowering—Findings
|
Urinary Sodium Excretion and Health Outcomes: Design
|
Urinary Sodium Excretion and Health Outcomes: CV Results
|
Urinary Sodium Excretion and Health Outcomes: Hypertension, BP Results
|
Systematic Review of CV Risk With NSAID Use: Design
|
Review of CV Risk with NSAID Use: Results
|